🏷

Classifications

Harrison's Part

👪

Inheritance

1

X-linked HP:0001417

Males are hemizygous and are the large majority of reported patients. Most male probands carry a de novo variant, but maternally inherited missense and nonsense variants occur, the mothers being unaffected or mildly affected. Affected females fall into two groups. Those with balanced X-autosome translocations, X-chromosome inversions or other rearrangements show strongly skewed X-inactivation in favour of the abnormal X, consistent with X-linked recessive expression. Females with de novo intragenic deletions or de novo loss-of-function or missense single-nucleotide variants have been reported with random X-inactivation in blood, which led one group to propose that loss-of-function alleles act as an X-linked dominant disorder while missense alleles act as X-linked recessive. Blood X-inactivation need not reflect the pattern in brain, so the dominant model is recorded as a proposal (see discussions), and the block is bound to the parent X-linked term rather than to either the recessive or the dominant child term.

X-linked inheritance

Show evidence (5 references)

CGGV:assertion_9305fb2c-6cdf-492d-9dd0-8b03dd4fab1c-2024-05-23T100000.000Z SUPPORT Other

"The majority of variants in male probands are de novo; however, there are some familial cases of mildly affected mothers."

ClinGen expert-panel summary of the inheritance pattern across the published probands: mostly de novo in males, with some maternally transmitted variants.

PMID:28589176 SUPPORT Human Clinical

"A total of 18 patients (including 5 females) were identified. Six had de novo, 5 had maternally inherited mutations, and 7 had chromosomal disruptions. All females had strongly skewed X-inactivation in favor of the abnormal X-chromosome."

Case series giving the de novo, maternally inherited and structural fractions, and documenting skewed X-inactivation in the affected females of that series.

PMID:21633362 SUPPORT Human Clinical

"Although this nonsense mutation was shared with the patient's mother, it was not observed in 100 normal individuals."

A maternally transmitted nonsense variant in an affected male.

+ 2 more references

◈

Mechanistic Hypotheses

2

Hyperekplexia in ARHGEF9 disease reflects loss of gephyrin-dependent glycine receptor clustering

glycinergic_hyperekplexia ALTERNATIVE

Evidence balance 3 support 1 refute

Proposed when the first patient, who had both hyperekplexia and epilepsy, was reported. It conflicts with the collybistin knockout mouse, in which glycine receptor localization is preserved, and with the rarity of hyperekplexia in later case series; it is consistent with the exaggerated startle of the G55A knock-in mouse. Whether the startle phenotype is glycinergic, specific to dominant-negative alleles such as G55A, or of another origin is unresolved.

Pathograph links

Impaired Gephyrin Clustering at Inhibitory Postsynapses -> Impaired Gephyrin-Dependent Glycine Receptor Clustering UNKNOWN Gephyrin also anchors glycine receptors, so a glycinergic defect was proposed to explain hyperekplexia in the first patient. The collybistin knockout mouse argues against a general requirement.

Impaired Gephyrin-Dependent Glycine Receptor Clustering -> Exaggerated startle response UNKNOWN

Show evidence (4 references)

PMID:15215304 SUPPORT In Vitro

"This mislocalization of GABAA receptors, together with a corresponding expected deficit in glycine receptor trafficking in brain stem and spinal cord neurons, is likely to be causal for the clinical phenotype of the patient described above."

The original authors' mechanistic interpretation of the G55A patient. The glycine receptor deficit is an expectation they draw from cultured-neuron data, not a measurement in brainstem or spinal cord.

PMID:17690689 REFUTE Model Organism

"Together, our data indicate that Cb is essential for gephyrin-dependent clustering of a specific set of GABAA receptors, but not required for glycine receptor postsynaptic localization."

Contradicts a general requirement for collybistin at glycinergic synapses.

PMID:33842008 SUPPORT In Vitro

"Our data suggest a novel interaction between α1 GlyR subunits and collybistin, which is physiologically relevant in vitro and in vivo and may contribute to postsynaptic anchoring of glycine receptors."

A direct collybistin PH-domain interaction with the glycine receptor alpha1 subunit, a route by which collybistin could matter at glycinergic synapses; not tested in an ARHGEF9 disease model.

+ 1 more reference

Loss of collybistin disinhibits mTORC1 signalling, contributing to the neurodevelopmental phenotype

collybistin_mtorc1_disinhibition EMERGING

Evidence balance 1 support

A gephyrin-independent consequence of collybistin loss, shown in patient iPSC-derived neural progenitors. Recorded as emerging because it rests on one cell-culture study and no in vivo or patient-level readout.

Pathograph links

ARHGEF9 Loss of Function -> Disinhibited mTORC1 Signaling UNKNOWN Collybistin binds mTOR and restrains mTORC1 signalling; its loss is proposed to disinhibit the pathway. This is a second, gephyrin-independent consequence of loss of function.

Disinhibited mTORC1 Signaling -> Intellectual disability UNKNOWN

Show evidence (1 reference)

PMID:25898924 SUPPORT In Vitro

"These findings suggest that disinhibited mTORC1 signaling may also contribute to the pathological process in patients with loss-of-function variants in CB."

Source of the hypothesis.

?

Discussions and Knowledge Gaps

2

Are ARHGEF9 loss-of-function alleles X-linked dominant, or is disease in heterozygous females explained by skewed X-inactivation in brain that blood does not show?

CONTROVERSY OPEN controversy_arhgef9_female_expression

Attached to

inheritance#X-linked

The early affected females all carried chromosomal rearrangements with strongly skewed X-inactivation in favour of the abnormal X. Later females with de novo intragenic deletions or single-nucleotide variants had random X-inactivation in blood, prompting a proposal that loss-of-function alleles behave as X-linked dominant. Blood X-inactivation is an imperfect proxy for brain, and variants transmitted by mildly affected or unaffected mothers complicate the picture. The answer changes recurrence counselling for the mothers and sisters of affected boys.

Show evidence (2 references)

PMID:33600053 SUPPORT Human Clinical

"Up to now, sequence variants and gross deletions have been identified in males, while only chromosomal aberrations have been reported in affected females who showed a skewed pattern of X-chromosome inactivation (XCI), suggesting an X-linked recessive (XLR) disorder."

States the earlier recessive interpretation that the paper then challenges.

PMID:32939676 SUPPORT Human Clinical

"Sanger sequencing revealed that these variants were de novo. The X-inactivation pattern in peripheral blood cells was random."

Two further affected females with de novo missense variants and random blood X-inactivation.

What causes the exaggerated startle in the minority of ARHGEF9 patients who have it, given that collybistin-null mice keep glycine receptors at their synapses while mice carrying the G55A patient variant show hyperekplexia?

HUMAN MODEL MISMATCH OPEN mismatch_arhgef9_hyperekplexia_mechanism

Attached to

pathophysiology#Impaired Gephyrin-Dependent Glycine Receptor Clustering phenotypes#Exaggerated startle response

The glycinergic explanation rests on the index patient and on gephyrin's role at glycinergic synapses. The null mouse preserves glycine receptor localization, and hyperekplexia is absent from most later patients. The G55A knock-in mouse does show an exaggerated startle, which fits an allele-specific (possibly dominant-negative) effect that a null cannot model; but glycine receptor clustering in brainstem and spinal cord of that model, the direct test of the glycinergic hypothesis, is not what its report examined.

Show evidence (2 references)

PMID:17690689 SUPPORT Model Organism

"Together, our data indicate that Cb is essential for gephyrin-dependent clustering of a specific set of GABAA receptors, but not required for glycine receptor postsynaptic localization."

The null-model result that conflicts with the clinical hypothesis.

PMID:39374387 SUPPORT Model Organism

"Consistent with ARHGEF9-DEE patients, Arhgef9G55A/Y mice were found to exhibit hyperekplexia and multiple seizure types"

The allele-specific model does reproduce the startle phenotype.

⚙

Pathophysiology

9

ARHGEF9 Loss of Function

Pathogenic ARHGEF9 alleles reduce or abolish collybistin function. The allelic series includes whole-gene and intragenic deletions, chromosomal rearrangements whose breakpoints disrupt the gene (in one female, leaving transcripts that no longer encode the PH domain), nonsense, frameshift and splice variants, and missense variants. Missense variants studied functionally act through distinct domains: G55A in the N-terminal SH3 domain, where the mutant protein aggregates and may act dominant-negatively; R290H in the catalytic DH domain, which weakens the DH-PH intramolecular interaction and lowers phosphatidylinositol 3-phosphate (PI3P) binding; and R338W and R356Q in the PH domain, which abolish PI3P binding. The missense proteins tested fail to cluster gephyrin normally. The disease-relevant activity is PH-domain membrane targeting rather than the protein's Cdc42 exchange activity: a collybistin mutant with no detectable Cdc42 GEF activity still builds gephyrin scaffolds, so the GEF activity is not recorded here as the lost function.

Loss of collybistin disinhibits mTORC1 signalling, contributing to the neurodevelopmental phenotype

ARHGEF9 hgnc:14561

Genetic context ARHGEF9 hgnc:14561 zygosity: HEMIZYGOUS functional_impact_category: LOSS_OF_FUNCTION

Hemizygous in affected males; affected females are heterozygous (see the inheritance block). Variant origin is mixed (de novo, maternally inherited, and structural), so it is not set here. The G55A SH3-domain allele may additionally act dominant-negatively.

phosphatidylinositol-3-phosphate binding GO:0032266 ↓ DECREASED

Downstream

Impaired Gephyrin Clustering at Inhibitory Postsynapses Collybistin is the factor that recruits gephyrin to the postsynaptic membrane; without functional collybistin, gephyrin is not clustered.

Disinhibited mTORC1 Signaling Collybistin binds mTOR and restrains mTORC1 signalling; its loss is proposed to disinhibit the pathway. This is a second, gephyrin-independent consequence of loss of function.

Show evidence (9 references)

PMID:21633362 SUPPORT Human Clinical

"Microarray-based comparative genomic hybridization analysis identified a 737-kb microdeletion of Xq11.1, including the cell division cycle 42 guanine nucleotide exchange factor (GEF)-9 gene (ARHGEF9), encoding collybistin"

Whole-gene deletion in an affected male, establishing loss of the gene as sufficient to cause disease.

PMID:17893116 SUPPORT Human Clinical

"We also found that the levels of the ARHGEF9 transcript from the patient are 10-fold less than those found in control samples."

A breakpoint-disrupted allele in an affected female reduces ARHGEF9 transcript tenfold, a direct measure of loss of expression.

PMID:18615734 SUPPORT Human Clinical

"These mRNAs no longer encode the pleckstrin homology (PH) domain of collybistin"

The translocation allele produces transcripts lacking the PH domain.

+ 6 more references

Impaired Gephyrin Clustering at Inhibitory Postsynapses

Gephyrin is the scaffold that anchors glycine receptors and major GABA-A receptor subtypes at inhibitory postsynapses. Collybistin, activated by the adhesion protein neuroligin-2 and anchored to the membrane through PI3P binding by its PH domain, is required to bring gephyrin to the membrane. In collybistin-deficient mice gephyrin fails to cluster at postsynaptic sites and accumulates as cytoplasmic aggregates, in a region-specific pattern (hippocampus and basolateral amygdala), and collybistin is needed both to form and to maintain these clusters.

Hyperekplexia in ARHGEF9 disease reflects loss of gephyrin-dependent glycine receptor clustering

hippocampal pyramidal neuron CL:1001571

gephyrin clustering involved in postsynaptic density assembly GO:0097116 ↓ DECREASED

inhibitory synapse GO:0060077

hippocampal formation UBERON:0002421 basolateral amygdala UBERON:0006107

Downstream

Loss of Postsynaptic GABA-A Receptor Clusters

Loss of Inhibitory Synapses at the Axon Initial Segment

Impaired Gephyrin-Dependent Glycine Receptor Clustering Gephyrin also anchors glycine receptors, so a glycinergic defect was proposed to explain hyperekplexia in the first patient. The collybistin knockout mouse argues against a general requirement.

Show evidence (4 references)

PMID:15215304 SUPPORT In Vitro

"We also demonstrate that gephyrin clustering in recombinant systems and cultured neurons requires both collybistin-gephyrin interactions and an intact collybistin pleckstrin homology domain."

Establishes the dependence of gephyrin clustering on collybistin.

PMID:18625319 SUPPORT Model Organism

"Our data show that Cb is required for both the initial localization and maintenance of gephyrin and gephyrin-dependent GABA(A)Rs at inhibitory postsynaptic membrane specializations in the hippocampus."

Conditional forebrain deletion in mice shows collybistin is needed for gephyrin clustering during synaptogenesis and afterwards.

PMID:18625319 SUPPORT Model Organism

"Deletion of Cb during embryonic development prevented gephyrin clustering during synaptogenesis and caused an accumulation of gephyrin aggregates in the cell body of CA1 pyramidal neurons."

Gephyrin aggregates in the soma when collybistin is absent.

+ 1 more reference

Loss of Postsynaptic GABA-A Receptor Clusters

Without clustered gephyrin, the gephyrin-dependent GABA-A receptors (notably alpha2-containing receptors, which bind collybistin directly) are lost from postsynaptic sites. The loss is selective, affecting a specific set of receptors and synapse types rather than all GABAergic synapses.

hippocampal pyramidal neuron CL:1001571

gamma-aminobutyric acid receptor clustering GO:0097112 ↓ DECREASED

GABA-ergic synapse GO:0098982

Animal models

Arhgef9 constitutive knockout mouse Mus musculus recapitulates

Downstream

Reduced GABAergic Synaptic Inhibition

Show evidence (2 references)

PMID:17690689 SUPPORT Model Organism

"Here we show that Cb-deficient mice display a region-specific loss of postsynaptic gephyrin and GABAA receptor clusters in the hippocampus and the basolateral amygdala."

Direct demonstration in the knockout mouse.

PMID:30087324 SUPPORT In Vitro

"Using isothermal titration calorimetry and complementary methods we demonstrate an exclusive low micromolar binding of collybistin to the α2-subunit of GABAARs."

Identifies the alpha2 subunit as the GABA-A receptor subunit that collybistin binds directly.

Loss of Inhibitory Synapses at the Axon Initial Segment

In the Arhgef9 G55A knock-in mouse, which carries the SH3-domain variant of the first reported patient, postsynaptic proteins aggregate, functional axo-axonic inhibitory synapses at the axon initial segment are lost, AIS architecture is disrupted and action potential generation is altered.

pyramidal neuron CL:0000598

axon initial segment GO:0043194

Animal models

Arhgef9 G55A knock-in mouse Mus musculus recapitulates

Downstream

Cortical and Hippocampal Network Hyperexcitability

Show evidence (1 reference)

PMID:39374387 SUPPORT Model Organism

"we observed aggregation of postsynaptic proteins and loss of functional inhibitory synapses at the axon initial segment (AIS), altered axo-axonic synaptic inhibition, disrupted action potential generation, and complex seizure phenotypes consistent with clinical observations."

Mouse knock-in of a patient-derived variant.

Reduced GABAergic Synaptic Inhibition

Loss of synaptic GABA-A receptor clusters reduces dendritic GABAergic inhibition of principal neurons, shifting the balance toward excitation.

hippocampal pyramidal neuron CL:1001571

synaptic transmission, GABAergic GO:0051932 ↓ DECREASED gamma-aminobutyric acid signaling pathway GO:0007214 ↓ DECREASED

Animal models

Gabra2-1 mouse (collybistin-alpha2 binding mutant) Mus musculus perturbs

Downstream

Cortical and Hippocampal Network Hyperexcitability

Altered Hippocampal Synaptic Plasticity

Show evidence (1 reference)

PMID:17690689 SUPPORT Model Organism

"Cb deficiency is accompanied by significant changes in hippocampal synaptic plasticity, due to reduced dendritic GABAergic inhibition."

Reduced dendritic GABAergic inhibition in knockout hippocampus.

Cortical and Hippocampal Network Hyperexcitability

Reduced synaptic and axo-axonic inhibition lowers the threshold for principal-cell firing. In collybistin-deficient mice the dentate gyrus shows a lower threshold for evoked population spikes, and the G55A knock-in mouse has spontaneous seizures of several types.

hippocampal formation UBERON:0002421

Animal models

Arhgef9 constitutive knockout mouse Mus musculus partially recapitulates

Downstream

Seizures

Epileptic encephalopathy Where the hyperexcitable network produces frequent, drug-resistant seizures, the course is encephalopathic. The step from the mouse network finding to the human encephalopathy is inferred.

Show evidence (1 reference)

PMID:19236916 SUPPORT Model Organism

"We found a decreased threshold for evoked population spikes of granule cells, indicating their increased excitability."

In vivo measure of increased excitability in the knockout.

Altered Hippocampal Synaptic Plasticity

Collybistin-deficient mice show abnormal hippocampal long-term potentiation, together with increased anxiety and impaired spatial learning. The direction of the LTP change differs between preparations: enhanced LTP and reduced LTD in slices, but reduced LTP induction in the dentate gyrus in vivo. The link from this plasticity change to intellectual disability in patients is inferred from the mouse behaviour and has not been tested in humans.

hippocampal formation UBERON:0002421

Downstream

Intellectual disability

Anxiety

Show evidence (2 references)

PMID:17690689 SUPPORT Model Organism

"Long-term potentiation is enhanced, and long-term depression reduced, in Cb-deficient hippocampal slices."

Slice electrophysiology in the knockout.

PMID:19236916 SUPPORT Model Organism

"In addition, the induction of long-term potentiation (LTP) was reduced."

In vivo LTP induction is reduced, in the opposite direction to the slice result; both are abnormal plasticity.

Impaired Gephyrin-Dependent Glycine Receptor Clustering

Proposed mechanism for hyperekplexia (exaggerated startle with neonatal stiffness), the hallmark of glycinergic synapse disorders, in the first reported patient. It is not established. In collybistin-knockout mice glycine receptors remain at postsynaptic sites, and hyperekplexia is absent in most later patients. On the other hand, mice carrying that patient's G55A variant do show an exaggerated acoustic startle, and the G55A protein aggregates with gephyrin and may act dominant-negatively, which a null allele would not. The node is kept so that the hyperekplexia phenotype is attached to its proposed mechanism and the uncertainty is visible.

Hyperekplexia in ARHGEF9 disease reflects loss of gephyrin-dependent glycine receptor clustering

glycine receptor clustering GO:0072579 ↓ DECREASED

glycinergic synapse GO:0098690

Animal models

Arhgef9 constitutive knockout mouse Mus musculus fails to recapitulate

Downstream

Exaggerated startle response

Show evidence (2 references)

PMID:15215304 SUPPORT Human Clinical

"The vital importance of collybistin for inhibitory synaptogenesis is underlined by the discovery of a mutation (G55A) in exon 2 of the human collybistin gene (ARHGEF9) in a patient with clinical symptoms of both hyperekplexia and epilepsy."

The clinical observation (hyperekplexia) that motivated the glycinergic hypothesis.

PMID:17690689 REFUTE Model Organism

"Together, our data indicate that Cb is essential for gephyrin-dependent clustering of a specific set of GABAA receptors, but not required for glycine receptor postsynaptic localization."

Glycine receptor localization is preserved in the knockout mouse.

Disinhibited mTORC1 Signaling

Collybistin binds mTOR and inhibits mTORC1 signalling and protein synthesis in neural progenitor cells. In iPSC-derived neural progenitors from a male with a whole-gene deletion, loss of collybistin is proposed to disinhibit mTORC1, a pathway implicated in other forms of intellectual disability and autism. This has been shown only in cultured cells and its contribution to the patient phenotype is untested.

Loss of collybistin disinhibits mTORC1 signalling, contributing to the neurodevelopmental phenotype

TOR signaling GO:0031929 ↑ INCREASED

Downstream

Intellectual disability

Show evidence (1 reference)

PMID:25898924 SUPPORT In Vitro

"These findings suggest that disinhibited mTORC1 signaling may also contribute to the pathological process in patients with loss-of-function variants in CB."

The authors state the mTORC1 disinhibition model as a possible contributor.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

26

Ear 1

Large fleshy earlobes Large earlobe HP:0009748

Show evidence (1 reference)

PMID:28589176 SUPPORT Human Clinical

"Facial dysmorphism, in particular, enlarged earlobes, midface hypoplasia, and prognathism appear to be a constant feature of the neurologically severely affected male patients."

The facial gestalt in severely affected males.

Head and Neck 3

Midface retrusion HP:0011800

Show evidence (1 reference)

PMID:28589176 SUPPORT Human Clinical

"Facial dysmorphism, in particular, enlarged earlobes, midface hypoplasia, and prognathism appear to be a constant feature of the neurologically severely affected male patients."

Midface hypoplasia is part of the gestalt.

Mandibular prognathia HP:0000303

Show evidence (1 reference)

PMID:28589176 SUPPORT Human Clinical

"Facial dysmorphism, in particular, enlarged earlobes, midface hypoplasia, and prognathism appear to be a constant feature of the neurologically severely affected male patients."

Prognathism is part of the gestalt.

Macrocephaly HP:0000256

Show evidence (2 references)

PMID:26834553 SUPPORT Human Clinical

"We report the resolution of a large family (K8010) with NS-XLID, with variable macrocephaly and macro-orchidism."

Variable macrocephaly segregating in one family.

PMID:21626670 SUPPORT Human Clinical

"We report on a novel Xq11.11 microdeletion in a patient presenting with severe mental retardation (MR), focal epilepsy, tall stature, macrocephaly, and dysmorphism."

Macrocephaly in a boy with a deletion; the deletion includes other genes, so attribution to ARHGEF9 is uncertain.

Integument 1

Persistent fetal finger and toe pads OCCASIONAL Prominent fingertip pads HP:0001212

Show evidence (1 reference)

PMID:28589176 SUPPORT Human Clinical

"fetal finger and toe pads (2), pigmentation abnormalities (2), pectus excavatum (2)"

2 of 18 patients (11%), the OCCASIONAL band.

Limbs 1

Fifth-finger clinodactyly OCCASIONAL Clinodactyly of the 5th finger HP:0004209

Show evidence (1 reference)

PMID:28589176 SUPPORT Human Clinical

"Two patients showed 5-digit clinodactyly."

2 of 18 patients (11%), the OCCASIONAL band.

Musculoskeletal 2

Neonatal hypertonia HP:0001276

Onset: NEONATAL

Show evidence (2 references)

ORPHA:163985 SUPPORT Other

"characterized by neonatal hypertonia which evolves to hypotonia and an exaggerated startle response"

Orphanet definition of the hyperekplexia-epilepsy presentation.

PMID:15215304 SUPPORT Human Clinical

"Immediately after delivery, cyanosis and muscular stiffness"

Clinical description of the index patient at birth.

Pectus excavatum OCCASIONAL HP:0000767

Show evidence (1 reference)

PMID:28589176 SUPPORT Human Clinical

"fetal finger and toe pads (2), pigmentation abnormalities (2), pectus excavatum (2)"

2 of 18 patients (11%), the OCCASIONAL band.

Nervous System 18

Intellectual disability VERY_FREQUENT HP:0001249

Show evidence (4 references)

PMID:28589176 SUPPORT Human Clinical

"All patients had ID ranging from mild (1) to moderate (7) to severe (10)."

18 of 18 patients had intellectual disability, supporting VERY_FREQUENT.

PMID:28589176 SUPPORT Human Clinical

"Intellectual disability was severe in most and moderate in patients with milder mutations."

Severity tracks the allele.

PMID:29130122 SUPPORT Human Clinical

"Further analysis revealed that all ARHGEF9 mutations were associated with intellectual disability, suggesting its critical role in psychomotor development."

Independent literature analysis reaching the same conclusion.

+ 1 more reference

Global developmental delay FREQUENT HP:0001263

Onset: INFANTILE

Show evidence (3 references)

PMID:28589176 SUPPORT Human Clinical

"The majority of patients (13) showed delayed early developmental milestones."

13 of 18 (72%), the FREQUENT band.

PMID:28589176 SUPPORT Human Clinical

"Symptoms presented in early childhood with delayed motor development alone or in combination with seizures."

Delayed motor development is the presenting feature.

PMID:28589176 SUPPORT Human Clinical

"Presenting symptoms: onset of symptoms occurred at a mean age of 15 months (median 9 months, range 1 day–7 years)."

Age at symptom onset.

Absent speech FREQUENT HP:0001344

Show evidence (1 reference)

PMID:28589176 SUPPORT Human Clinical

"Of the 10 patients with severe ID, 7 were nonverbal."

7 of 18 patients (39%) were nonverbal, the FREQUENT band.

Developmental regression HP:0002376

Show evidence (2 references)

PMID:34851771 SUPPORT Human Clinical

"Here, we report a boy with clinical symptoms of severe intellectual disability, epilepsy, and developmental delay and regression."

Case report of regression in a boy with a de novo frameshift variant.

ORPHA:163985 SUPPORT Other

"Progressive epileptic encephalopathy, intellectual disability, and psychomotor development arrest, with subsequent decline, may be additionally associated."

Orphanet definition includes developmental arrest and decline.

Seizures FREQUENT HP:0001250

Onset: INFANTILE; 0.02-7y

Show evidence (4 references)

PMID:28589176 SUPPORT Human Clinical

"Thirteen patients had epilepsy with onset at a mean age of 20 months (median 12 months, range 1 week–7 years)."

13 of 18 patients (72%) had epilepsy, the FREQUENT band, and gives the onset range.

PMID:28589176 SUPPORT Human Clinical

"Four patients had medically refractory epilepsy, 4 showed 50% seizure reduction with antiepileptic drugs (AEDs), 1 showed seizure reduction of less than 50%, and 2 became completely seizure free without further AED treatment."

Treatment response spans refractory to seizure-free.

PMID:28589176 SUPPORT Human Clinical

"Patients with mutations in exon 9 affecting the protein's PH domain did not develop epilepsy."

Genotype-phenotype exception at the mild end of the spectrum.

+ 1 more reference

Epileptic encephalopathy HP:0200134

Show evidence (4 references)

PMID:35638461 SUPPORT Human Clinical

"We described five patients with developmental and epileptic encephalopathy caused by ARHGEF9 gene variants."

Case series of DEE due to ARHGEF9.

PMID:35638461 SUPPORT Human Clinical

"the clinical phenotype of epilepsy is often refractory and the prognosis is poor."

Refractory course and poor prognosis in the epileptic phenotype.

PMID:15215304 SUPPORT Human Clinical

"Eventually, a progressive epileptic encephalopathy as well as hyperekplexia became evident and poly-drug treatment failed to provide adequate longterm seizure control."

Clinical course of the index patient.

+ 1 more reference

Bilateral tonic-clonic seizures HP:0002069

Show evidence (1 reference)

PMID:28589176 SUPPORT Human Clinical

"Seizure types were variable, including generalized tonic-clonic (9), focal dyscognitive (5), focal (4), myoclonic (1), and tonic (2) seizures."

Generalized tonic-clonic seizures in 9 of 13 patients with epilepsy.

Focal-onset seizures HP:0007359

Show evidence (2 references)

PMID:28589176 SUPPORT Human Clinical

"Seizure types were variable, including generalized tonic-clonic (9), focal dyscognitive (5), focal (4), myoclonic (1), and tonic (2) seizures."

Focal and focal dyscognitive seizures are the second most common types.

PMID:28620718 SUPPORT Human Clinical

"Three developed afebrile seizures between age 7-17 years. Three showed focal seizure semiology. None had hyperekplexia."

Focal epilepsy with later onset in a family with a hemizygous missense variant.

Tonic seizures HP:0032792

Show evidence (3 references)

ORPHA:163985 SUPPORT Other

"followed by the development of early-onset, frequently refractory, tonic or myoclonic seizures"

Orphanet definition names tonic and myoclonic seizures.

PMID:15215304 SUPPORT Human Clinical

"During the following weeks, the child developed tonic seizures that were provoked by tactile stimulation."

Neonatal-period tonic seizures in the index patient.

PMID:28589176 SUPPORT Human Clinical

"Seizure types were variable, including generalized tonic-clonic (9), focal dyscognitive (5), focal (4), myoclonic (1), and tonic (2) seizures."

Tonic seizures in 2 of 13 patients with epilepsy.

Febrile seizures Febrile seizure (within the age range of 3 months to 6 years) HP:0002373

Show evidence (1 reference)

PMID:28620718 SUPPORT Human Clinical

"All affected male siblings had febrile seizures from age 2-3 years and intellectual disability."

Febrile seizures in four hemizygous brothers.

Exaggerated startle response OCCASIONAL HP:0002267

Onset: NEONATAL

Show evidence (3 references)

PMID:15215304 SUPPORT Human Clinical

"EEG monitoring coupled with ambulatory video revealed that the seizures were both hyperekplectic and epileptic in origin."

The index patient.

PMID:28589176 SUPPORT Human Clinical

"One patient presented with hyperekplexia and seizures shortly after birth"

1 of 18 patients (about 6%), the OCCASIONAL band.

PMID:18615734 REFUTE Human Clinical

"We report the identification of a balanced chromosomal translocation in a female patient presenting with a disturbed sleep-wake cycle, late-onset epileptic seizures, increased anxiety, aggressive behavior, and mental retardation, but not hyperekplexia."

Documents absence of hyperekplexia in an affected female, showing it is not a constant feature.

Sensory hyperarousal Sensory hypersensitivity HP:5200058

Show evidence (1 reference)

PMID:17893116 SUPPORT Human Clinical

"We identified a female patient with mental retardation and sensory hyperarousal."

Case report of the phenotype.

EEG abnormality HP:0002353

Show evidence (3 references)

PMID:28589176 SUPPORT Human Clinical

"EEG findings were available for 11 of the 13 patients and showed generalized (3), bilateral (1), multifocal (1), and focal (1) epileptiform discharges and were normal in 2 patients."

EEG findings in the 18-patient series.

PMID:28589176 SUPPORT Human Clinical

"One patient with polymicrogyria showed continuous spike-and-wave discharges in slow-wave sleep."

Continuous spike-and-wave in sleep in one patient.

PMID:35169261 SUPPORT Human Clinical

"Evaluation of 41 ARHGEF9 patient reports shows ubiquitous inclusion of ID, along with other frequently reported symptoms of epilepsy, abnormal baseline EEG activity, behavioral symptoms, and sleep disturbances."

Literature review naming abnormal baseline EEG as a frequently reported feature.

Autistic behavior OCCASIONAL HP:0000729

Show evidence (3 references)

PMID:28589176 SUPPORT Human Clinical

"Autistic features were reported in 4 patients. Five patients had hyperactivity."

4 of 18 (22%), the OCCASIONAL band.

PMID:30048823 SUPPORT Human Clinical

"We report two unrelated females with autism and mild intellectual disability."

Autism in two females with de novo ARHGEF9 deletions.

PMID:27238888 SUPPORT Human Clinical

"We report an 8-year-old female with autism spectrum disorder (ASD), intellectual disability and speech delay who was found to carry a de novo 82 kb deletion of chromosome Xq11.1-11.2 involving the ARHGEF9 gene on chromosomal microarray."

A further girl with autism and a de novo deletion including ARHGEF9.

Hyperactivity OCCASIONAL HP:0000752

Show evidence (1 reference)

PMID:28589176 SUPPORT Human Clinical

"Autistic features were reported in 4 patients. Five patients had hyperactivity."

5 of 18 (28%), the OCCASIONAL band.

Anxiety HP:0000739

Show evidence (1 reference)

PMID:18615734 SUPPORT Human Clinical

"We report the identification of a balanced chromosomal translocation in a female patient presenting with a disturbed sleep-wake cycle, late-onset epileptic seizures, increased anxiety, aggressive behavior, and mental retardation, but not hyperekplexia."

Increased anxiety in a female with a gene-disrupting translocation.

Aggressive behavior HP:0000718

Show evidence (2 references)

PMID:18615734 SUPPORT Human Clinical

"We report the identification of a balanced chromosomal translocation in a female patient presenting with a disturbed sleep-wake cycle, late-onset epileptic seizures, increased anxiety, aggressive behavior, and mental retardation, but not hyperekplexia."

Aggressive behaviour in the same patient.

PMID:28589176 SUPPORT Human Clinical

"Additional features included sleep disorder (4), ataxic gait (1), aggressive behavior (2)"

Aggressive behaviour in 2 of 18 patients.

Sleep disturbance HP:0002360

Show evidence (2 references)

PMID:28589176 SUPPORT Human Clinical

"Additional features included sleep disorder (4), ataxic gait (1), aggressive behavior (2)"

Sleep disorder in 4 of 18 patients.

PMID:35169261 SUPPORT Human Clinical

"Evaluation of 41 ARHGEF9 patient reports shows ubiquitous inclusion of ID, along with other frequently reported symptoms of epilepsy, abnormal baseline EEG activity, behavioral symptoms, and sleep disturbances."

Sleep disturbance is among the frequently reported features in a 41-report review.

🧬

Genetic Associations

1

ARHGEF9 (ARHGEF9 (Xq11.1) encodes collybistin. ClinGen classifies ARHGEF9 as Definitive for X-linked complex neurodevelopmental disorder, the broader MONDO grouping under which DEE8 sits. Pathogenic alleles include missense, nonsense, frameshift and splice variants, intragenic and whole-gene deletions, and balanced rearrangements disrupting the gene. Missense variants confined to the PH domain are associated with intellectual disability without epilepsy, whereas complete loss of the gene and severe DH-domain variants are associated with severe epilepsy.)

Gene: ARHGEF9 hgnc:14561 relationship_type: CAUSATIVE

Show evidence (4 references)

CGGV:assertion_9305fb2c-6cdf-492d-9dd0-8b03dd4fab1c-2024-05-23T100000.000Z SUPPORT Other

ClinGen gene-disease validity: Definitive (Intellectual Disability and Autism GCEP, SOP10, 2024-05-23). The assertion is against the broader MONDO:0100148 grouping, not against MONDO:0010375 itself.

CGGV:assertion_9305fb2c-6cdf-492d-9dd0-8b03dd4fab1c-2024-05-23T100000.000Z SUPPORT Other

"The molecular spectrum of ARHGEF9 variants include missense, copy number variants, frameshift, nonsense, and structural X-chromosome abnormalities"

ClinGen summary of the allelic spectrum.

PMID:29130122 SUPPORT Human Clinical

"Three missense mutations in the PH domain were not associated with epilepsy, suggesting that the co-occurrence of epilepsy depends on the affected functional domains. Missense mutations with severe molecular alteration in the DH domain, or located in the DH-gephyrin binding region, or adjacent..."

Domain-based genotype-phenotype correlation.

+ 1 more reference

💊

Medical Actions

2

Antiseizure medication

Action: Pharmacotherapy NCIT:C15986

Agent: valproic acid CHEBI:39867 levetiracetam CHEBI:6437

Platform: Small molecule

There is no disease-specific therapy. Seizures are treated with standard antiseizure medications, usually in combination, and response ranges from seizure freedom to drug resistance. Valproic acid and levetiracetam were each reported effective in individual patients in one small series, which is case-level evidence rather than a comparative result.

Target Phenotypes: Seizure HP:0001250

Show evidence (2 references)

PMID:35638461 SUPPORT Human Clinical

"Among them, the antiepileptic treatment of valproic acid and levetiracetam was effective in two cases individually."

Case-level report of response to valproic acid and levetiracetam.

PMID:28589176 SUPPORT Human Clinical

"AEDs consisted mainly of combination therapy (10); only 1 patient was on monotherapy (1)."

Most treated patients need polytherapy.

Clonazepam

Action: Pharmacotherapy NCIT:C15986

Agent: clonazepam CHEBI:3756

Platform: Small molecule

Clonazepam is the usual symptomatic treatment for hyperekplexia. In the one ARHGEF9 patient in whom its effect on hyperekplexia is reported, the index G55A patient, it was unsuccessful. That is a single case, so it records a failure rather than establishing that clonazepam does not work in ARHGEF9 disease.

Target Phenotypes: Exaggerated startle response HP:0002267

Show evidence (1 reference)

PMID:15215304 REFUTE Human Clinical

"At 4 months of age, a diagnosis of hyperekplexia was made, but therapy with clonazepam was unsuccessful."

Clonazepam failed for hyperekplexia in the index patient.

🔬

Diagnosis

3

Chromosomal microarray

Diagnosis is molecular. Because a large share of reported ARHGEF9 disease is due to deletions and chromosomal disruptions (7 of 18 patients in the largest series had chromosomal disruptions), chromosomal microarray is recommended as the first-line test. In a female, a balanced rearrangement disrupting the gene will not be seen on microarray and needs karyotype or breakpoint mapping.

chromosomal microarray NCIT:C198497

Show evidence (2 references)

PMID:28589176 SUPPORT Human Clinical

"Therefore, the diagnostic approach in candidate patients still requires chromosomal microarray testing as the first-line genetic testing because of the substantial diagnostic yield and low relative cost, followed by a gene panel or whole-exome sequencing approach as second tier."

Recommendation from the 18-patient series.

PMID:28589176 SUPPORT Human Clinical

"A total of 18 patients (including 5 females) were identified. Six had de novo, 5 had maternally inherited mutations, and 7 had chromosomal disruptions."

The chromosomal-disruption fraction behind the first-line recommendation.

Gene panel or exome sequencing

Second-tier testing for sequence variants (missense, nonsense, frameshift, splice) by an epilepsy or intellectual-disability gene panel or by exome sequencing. Parental testing distinguishes de novo from maternally inherited variants, which matters for counselling the mother.

gene panel or whole-exome sequencing NCIT:C15709

Show evidence (1 reference)

PMID:28589176 SUPPORT Human Clinical

"Therefore, the diagnostic approach in candidate patients still requires chromosomal microarray testing as the first-line genetic testing because of the substantial diagnostic yield and low relative cost, followed by a gene panel or whole-exome sequencing approach as second tier."

Panel or exome sequencing is the recommended second tier.

Electroencephalography

EEG documents epileptiform activity and the encephalopathic background. It is not specific for ARHGEF9 disease; findings range from normal to generalized, multifocal or focal discharges, and continuous spike-and-wave in sleep was seen in one patient.

Electroencephalography NCIT:C38054

Show evidence (2 references)

PMID:28589176 SUPPORT Human Clinical

"EEG findings were available for 11 of the 13 patients and showed generalized (3), bilateral (1), multifocal (1), and focal (1) epileptiform discharges and were normal in 2 patients."

Range of EEG findings in the 18-patient series.

PMID:15215304 SUPPORT Human Clinical

"EEG monitoring coupled with ambulatory video revealed that the seizures were both hyperekplectic and epileptic in origin."

Video-EEG separated hyperekplectic from epileptic events in the index patient.

📊

Prevalence

1

Worldwide

Cases In Literature Not yet documented

No population prevalence or incidence estimate has been published. Case counts in literature reviews were about 40 by 2022 (41 patient reports in one review, 40 children in another). The Orphanet record for hyperekplexia-epilepsy syndrome (ORPHA:163985) carries a definition but no epidemiology row.

Show evidence (2 references)

PMID:35169261 SUPPORT Human Clinical

"Evaluation of 41 ARHGEF9 patient reports shows ubiquitous inclusion of ID"

Literature case count used for the CASES_IN_LITERATURE record.

PMID:35638461 SUPPORT Human Clinical

"So far, a total of 40 children with ARHGEF9 gene variants have been reported."

Independent literature count of the same order.

🐁

Animal Models

3

Arhgef9 constitutive knockout mouse

Constitutive collybistin knockout. Gephyrin and GABA-A receptor clusters are lost in a region-specific way from hippocampus and basolateral amygdala, dendritic GABAergic inhibition is reduced, hippocampal plasticity is abnormal, dentate gyrus excitability is increased in vivo, and the animals show increased anxiety and impaired spatial learning. Glycine receptor localization is preserved. Conditional forebrain deletion shows collybistin is needed both to form and to maintain these synapses.

Species

Mus musculus

Genotype

Arhgef9 null (collybistin-deficient)

Genes

ARHGEF9 hgnc:14561

Publication

PMID:17690689

Pathograph links

Loss of Postsynaptic GABA-A Receptor Clusters recapitulates fidelity: moderate

Limitations: Mouse null allele; the loss is region-specific in the mouse, and the human brain distribution of the defect is unknown.

Show evidence (1 reference)

PMID:17690689 SUPPORT Model Organism

"Here we show that Cb-deficient mice display a region-specific loss of postsynaptic gephyrin and GABAA receptor clusters in the hippocampus and the basolateral amygdala."

Shows the model reproduces the receptor-clustering node.

Impaired Gephyrin-Dependent Glycine Receptor Clustering fails to recapitulate fidelity: unknown

Limitations: Glycine receptor postsynaptic localization is preserved in the null mouse, so it does not model a glycinergic basis for the hyperekplexia seen in the SH3-domain G55A patient; a dominant-negative allele effect would not be captured by a null.

Show evidence (1 reference)

PMID:17690689 SUPPORT Model Organism

"Together, our data indicate that Cb is essential for gephyrin-dependent clustering of a specific set of GABAA receptors, but not required for glycine receptor postsynaptic localization."

The negative result on glycine receptors.

Cortical and Hippocampal Network Hyperexcitability partially recapitulates fidelity: moderate

Limitations: Shows increased evoked excitability of dentate granule cells in vivo; the constitutive-knockout papers cited here do not report spontaneous seizures.

Show evidence (1 reference)

PMID:19236916 SUPPORT Model Organism

"We found a decreased threshold for evoked population spikes of granule cells, indicating their increased excitability."

Evoked network hyperexcitability in vivo.

Show evidence (1 reference)

PMID:17690689 SUPPORT Model Organism

"Consistent with the anatomical and electrophysiological findings, the animals show increased levels of anxiety and impaired spatial learning."

Behavioural phenotype of the model.

Arhgef9 G55A knock-in mouse

Knock-in of the G55A variant found in the first reported patient, who had hyperekplexia and a fatal epileptic encephalopathy. Postsynaptic proteins aggregate, inhibitory synapses at the axon initial segment are lost, action potential generation is disrupted, and the mice have an exaggerated acoustic startle and generalized tonic-clonic, tonic and spike-wave seizures.

Species

Mus musculus

Genotype

Arhgef9 G55A/Y (hemizygous knock-in of the index-patient SH3-domain variant)

Genes

ARHGEF9 hgnc:14561

Publication

PMID:39374387

Pathograph links

Loss of Inhibitory Synapses at the Axon Initial Segment recapitulates fidelity: moderate

Limitations: Models one severe missense allele; whether the AIS defect generalizes to null or PH-domain alleles is not tested, and AIS pathology has not been examined in patient tissue.

Show evidence (1 reference)

PMID:39374387 SUPPORT Model Organism

"In a mouse model carrying a patient-derived ARHGEF9 variant associated with severe disease, we observed aggregation of postsynaptic proteins and loss of functional inhibitory synapses at the axon initial segment (AIS)"

Direct observation in the model.

Show evidence (2 references)

PMID:39374387 SUPPORT Model Organism

"The G55A variant also causes behavioral impairment and the generation of multiple seizure types including convulsive generalized tonic-clonic, tonic, spike-wave discharges, as well as interictal spikes."

Seizure phenotype of the model.

PMID:39374387 SUPPORT Model Organism

"Consistent with ARHGEF9-DEE patients, Arhgef9G55A/Y mice were found to exhibit hyperekplexia and multiple seizure types"

Startle phenotype of the model.

Gabra2-1 mouse (collybistin-alpha2 binding mutant)

Not an Arhgef9 allele. The collybistin-binding motif of the GABA-A receptor alpha2 subunit is replaced, which down-regulates collybistin, particularly at cholecystokinin basket-cell synapses. The mice have developmental seizures with early mortality, anxiety, hyperactivity, memory deficits and reduced social preference, which the authors present as a phenocopy of human ARHGEF9 disease. EEG and anxiety phenotypes were ameliorated by the alpha2/alpha3-selective positive modulator AZD7325.

Species

Mus musculus

Genotype

Gabra2-1 (collybistin-binding motif of the GABA-A receptor alpha2 subunit replaced by the alpha1 gephyrin-binding motif)

Genes

GABRA2 hgnc:4076

Publication

PMID:30087324

Pathograph links

Reduced GABAergic Synaptic Inhibition perturbs fidelity: moderate

Limitations: Perturbs one collybistin-receptor interaction rather than collybistin itself; it isolates the alpha2 arm of the mechanism and cannot model gephyrin-wide or mTORC1 effects.

Show evidence (1 reference)

PMID:30087324 SUPPORT Model Organism

"The mutation results in loss of a distinct subset of inhibitory synapses and decreased amplitude of inhibitory synaptic currents."

Reduced inhibitory synaptic current in the model.

Show evidence (4 references)

PMID:35169261 SUPPORT Model Organism

"The Gabra2-1 mutation causes a strong downregulation of Cb expression, particularly at cholecystokinin basket cell inhibitory synapses."

Collybistin loss at a defined synapse type in the model.

PMID:35169261 SUPPORT Model Organism

"Gabra2-1 mice have deficits in working and recognition memory, as well as hyperactivity, anxiety, and reduced social preference, recapitulating the frequently reported features of ARHGEF9 patients."

Behavioural phenocopy.

PMID:35169261 SUPPORT Model Organism

"Gabra2-1 mice also have spontaneous seizures during postnatal development which can lead to mortality, and baseline abnormalities in low-frequency wavelengths of the EEG."

Developmental seizures and mortality in the phenocopy model.

+ 1 more reference

{ }

Source YAML

click to show

name: Developmental and Epileptic Encephalopathy 8
creation_date: "2026-09-23T00:00:00Z"
category: Mendelian
description: >-
  Developmental and epileptic encephalopathy 8 (DEE8) is the X-linked
  neurodevelopmental disorder caused by pathogenic variants in ARHGEF9 on Xq11.1,
  which encodes collybistin, a brain-specific guanine nucleotide exchange factor
  that recruits the scaffolding protein gephyrin to the postsynaptic membrane of
  inhibitory synapses. Loss of collybistin function impairs gephyrin clustering
  and, with it, the synaptic clustering of gephyrin-dependent GABA-A receptors,
  reducing GABAergic inhibition. The phenotype is broader than the MONDO label
  suggests. Intellectual disability is the constant feature and is usually
  moderate to severe; roughly 70% of patients in the largest clinical series
  also have epilepsy, which begins in infancy or early childhood (median onset
  12 months, range one week to 7 years) and is drug-resistant in a subset. The
  first reported patient had neonatal stiffness and hyperekplexia followed by a
  fatal progressive epileptic encephalopathy, which is where the
  "hyperekplexia-epilepsy syndrome" synonym comes from; hyperekplexia has since
  proved uncommon. At the mild end, missense variants confined to the pleckstrin
  homology (PH) domain cause intellectual disability without epilepsy. Severely
  affected boys often share a facial gestalt of large fleshy earlobes, midface
  hypoplasia and prognathism, and autistic features, hyperactivity, anxiety,
  aggression and sleep disturbance recur. Most affected males carry a de novo
  variant, but maternally inherited variants from mildly affected or unaffected
  mothers occur. Affected females are reported both with strongly skewed
  X-inactivation (mostly chromosomal rearrangements) and with random
  X-inactivation in blood (de novo intragenic deletions and single-nucleotide
  variants), and whether loss-of-function alleles behave as X-linked dominant is
  unsettled.
parents:
- Developmental and Epileptic Encephalopathy
- X-Linked Intellectual Disability
synonyms:
- DEE8
- EIEE8
- developmental and epileptic encephalopathy 8
- epileptic encephalopathy, early infantile, 8
- early infantile epileptic encephalopathy 8
- hyperekplexia and epilepsy
- hyperekplexia-epilepsy syndrome
- ARHGEF9-related neurodevelopmental disorder
- ARHGEF9 disease
- collybistin deficiency
disease_term:
  preferred_term: ARHGEF9-related developmental and epileptic encephalopathy
  term:
    id: MONDO:0010375
    label: developmental and epileptic encephalopathy, 8
classifications:
  harrisons_chapter:
  - classification_value: NEUROLOGIC
    evidence:
    - reference: PMID:21633362
      reference_title: "Loss-of-function mutation of collybistin is responsible for X-linked mental retardation associated with epilepsy."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        The common phenotypic effects of all ARHGEF9 mutations were mental retardation and epilepsy.
      explanation: >-
        Intellectual disability with epilepsy places the disorder in the
        neurologic Part.
  - classification_value: GENETICS_ENVIRONMENT_DISEASE
    evidence:
    - reference: PMID:21633362
      reference_title: "Loss-of-function mutation of collybistin is responsible for X-linked mental retardation associated with epilepsy."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Therefore, ARHGEF9 is likely to be responsible for syndromic X-linked mental retardation associated with epilepsy.
      explanation: >-
        A single-gene X-linked disorder, so the genetics Part also applies.

inheritance:
- name: X-linked
  inheritance_term:
    preferred_term: X-linked inheritance
    term:
      id: HP:0001417
      label: X-linked inheritance
  description: >-
    Males are hemizygous and are the large majority of reported patients. Most
    male probands carry a de novo variant, but maternally inherited missense and
    nonsense variants occur, the mothers being unaffected or mildly affected.
    Affected females fall into two groups. Those with balanced X-autosome
    translocations, X-chromosome inversions or other rearrangements show
    strongly skewed X-inactivation in favour of the abnormal X, consistent with
    X-linked recessive expression. Females with de novo intragenic deletions or
    de novo loss-of-function or missense single-nucleotide variants have been
    reported with random X-inactivation in blood, which led one group to propose
    that loss-of-function alleles act as an X-linked dominant disorder while
    missense alleles act as X-linked recessive. Blood X-inactivation need not
    reflect the pattern in brain, so the dominant model is recorded as a
    proposal (see discussions), and the block is bound to the parent X-linked
    term rather than to either the recessive or the dominant child term.
  evidence:
  - reference: CGGV:assertion_9305fb2c-6cdf-492d-9dd0-8b03dd4fab1c-2024-05-23T100000.000Z
    reference_title: "ARHGEF9 / X-linked complex neurodevelopmental disorder (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The majority of variants in male probands are de novo; however, there are some familial cases of mildly affected mothers.
    explanation: >-
      ClinGen expert-panel summary of the inheritance pattern across the
      published probands: mostly de novo in males, with some maternally
      transmitted variants.
  - reference: PMID:28589176
    reference_title: "ARHGEF9 disease: Phenotype clarification and genotype-phenotype correlation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A total of 18 patients (including 5 females) were identified. Six had de novo, 5 had maternally inherited mutations, and 7 had chromosomal disruptions. All females had strongly skewed X-inactivation in favor of the abnormal X-chromosome.
    explanation: >-
      Case series giving the de novo, maternally inherited and structural
      fractions, and documenting skewed X-inactivation in the affected females
      of that series.
  - reference: PMID:21633362
    reference_title: "Loss-of-function mutation of collybistin is responsible for X-linked mental retardation associated with epilepsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Although this nonsense mutation was shared with the patient's mother, it was not observed in 100 normal individuals.
    explanation: >-
      A maternally transmitted nonsense variant in an affected male.
  - reference: PMID:33600053
    reference_title: "Loss-of-function variants in ARHGEF9 are associated with an X-linked intellectual disability dominant disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Both females showed a random XCI. Thus, we suggest that missense variants are responsible for an XLR disorder affecting males and that LoF variants, mainly occurring de novo, may be responsible for an X-linked dominant disorder affecting males and females.
    explanation: >-
      Two affected females with loss-of-function variants and random
      X-inactivation, and the authors' proposed split between recessive
      (missense) and dominant (loss-of-function) behaviour.
  - reference: PMID:30048823
    reference_title: "Autism spectrum disorder in females with ARHGEF9 alterations and a random pattern of X chromosome inactivation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Peripheral blood samples revealed random X-chromosome inactivation in both patients.
    explanation: >-
      Two further affected females, with de novo intragenic deletions, and
      random X-inactivation in blood.

prevalence:
- population: Worldwide
  measure_type: CASES_IN_LITERATURE
  prevalence_class: NOT_YET_DOCUMENTED
  notes: >-
    No population prevalence or incidence estimate has been published. Case
    counts in literature reviews were about 40 by 2022 (41 patient reports in one
    review, 40 children in another). The Orphanet record for
    hyperekplexia-epilepsy syndrome (ORPHA:163985) carries a definition but no
    epidemiology row.
  evidence:
  - reference: PMID:35169261
    reference_title: "Human ARHGEF9 intellectual disability syndrome is phenocopied by a mutation that disrupts collybistin binding to the GABA(A) receptor α2 subunit."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Evaluation of 41 ARHGEF9 patient reports shows ubiquitous inclusion of ID
    explanation: >-
      Literature case count used for the CASES_IN_LITERATURE record.
  - reference: PMID:35638461
    reference_title: "ARHGEF9 gene variant leads to developmental and epileptic encephalopathy: Genotypic phenotype analysis and treatment exploration."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      So far, a total of 40 children with ARHGEF9 gene variants have been reported.
    explanation: >-
      Independent literature count of the same order.

pathophysiology:
- name: ARHGEF9 Loss of Function
  role: trigger
  biological_scale: MOLECULAR
  description: >-
    Pathogenic ARHGEF9 alleles reduce or abolish collybistin function. The
    allelic series includes whole-gene and intragenic deletions, chromosomal
    rearrangements whose breakpoints disrupt the gene (in one female, leaving
    transcripts that no longer encode the PH domain), nonsense, frameshift and
    splice variants, and missense variants. Missense variants studied
    functionally act through distinct domains: G55A in the N-terminal SH3
    domain, where the mutant protein aggregates and may act dominant-negatively;
    R290H in the catalytic DH domain, which weakens the DH-PH intramolecular
    interaction and lowers phosphatidylinositol 3-phosphate (PI3P) binding; and
    R338W and R356Q in the PH domain, which abolish PI3P binding. The missense
    proteins tested fail to cluster gephyrin normally. The disease-relevant
    activity is PH-domain membrane targeting rather than the protein's Cdc42
    exchange activity: a collybistin mutant with no detectable Cdc42 GEF
    activity still builds gephyrin scaffolds, so the GEF activity is not
    recorded here as the lost function.
  genes:
  - preferred_term: ARHGEF9
    term:
      id: hgnc:14561
      label: ARHGEF9
  genetic_context:
    gene:
      preferred_term: ARHGEF9
      term:
        id: hgnc:14561
        label: ARHGEF9
    zygosity: HEMIZYGOUS
    functional_impact_category: LOSS_OF_FUNCTION
    notes: >-
      Hemizygous in affected males; affected females are heterozygous (see the
      inheritance block). Variant origin is mixed (de novo, maternally
      inherited, and structural), so it is not set here. The G55A SH3-domain
      allele may additionally act dominant-negatively.
  molecular_functions:
  - preferred_term: phosphatidylinositol-3-phosphate binding
    term:
      id: GO:0032266
      label: phosphatidylinositol-3-phosphate binding
    modifier: DECREASED
  evidence:
  - reference: PMID:21633362
    reference_title: "Loss-of-function mutation of collybistin is responsible for X-linked mental retardation associated with epilepsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Microarray-based comparative genomic hybridization analysis identified a 737-kb microdeletion of Xq11.1, including the cell division cycle 42 guanine nucleotide exchange factor (GEF)-9 gene (ARHGEF9), encoding collybistin
    explanation: >-
      Whole-gene deletion in an affected male, establishing loss of the gene as
      sufficient to cause disease.
  - reference: PMID:17893116
    reference_title: "ARHGEF9 disruption in a female patient is associated with X linked mental retardation and sensory hyperarousal."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We also found that the levels of the ARHGEF9 transcript from the patient are 10-fold less than those found in control samples.
    explanation: >-
      A breakpoint-disrupted allele in an affected female reduces ARHGEF9
      transcript tenfold, a direct measure of loss of expression.
  - reference: PMID:18615734
    reference_title: "A balanced chromosomal translocation disrupting ARHGEF9 is associated with epilepsy, anxiety, aggression, and mental retardation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      These mRNAs no longer encode the pleckstrin homology (PH) domain of collybistin
    explanation: >-
      The translocation allele produces transcripts lacking the PH domain.
  - reference: PMID:25678704
    reference_title: "Lipid binding defects and perturbed synaptogenic activity of a Collybistin R290H mutant that causes epilepsy and intellectual disability."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      we demonstrate that the R290H mutation alters the strength of intramolecular interactions between the diffuse B-cell lymphoma homology domain and the pleckstrin homology domain of Cb. This defect reduces the phosphatidylinositol 3-phosphate binding affinity of Cb, which limits its normal synaptogenic activity.
    explanation: >-
      Biochemical mechanism for a DH-domain missense variant found in a patient
      with epilepsy and intellectual disability.
  - reference: PMID:26834553
    reference_title: "Missense Mutation R338W in ARHGEF9 in a Family with X-linked Intellectual Disability with Variable Macrocephaly and Macro-Orchidism."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      functional assays revealed that recombinant CB CB2SH3- (R338W) was deficient in PI3P binding and was not able to translocate EGFP-gephyrin to submembrane microaggregates in an in vitro clustering assay.
    explanation: >-
      A PH-domain missense variant abolishes PI3P binding and gephyrin
      translocation.
  - reference: PMID:20345913
    reference_title: "PH-domain-driven targeting of collybistin but not Cdc42 activation is required for synaptic gephyrin clustering."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      A Cb II mutant lacking any detectable GEF activity towards Cdc42 was still fully active in inducing gephyrin scaffold formation, both in transfected NIH-3T3 cells and in cultured hippocampal neurons.
    explanation: >-
      Cdc42 exchange activity is dispensable for gephyrin scaffold formation in
      cells and neurons.
  - reference: PMID:20345913
    reference_title: "PH-domain-driven targeting of collybistin but not Cdc42 activation is required for synaptic gephyrin clustering."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Furthermore, mice with a forebrain-specific inactivation of the Cdc42 gene displayed normal densities of gephyrin and GABA(A) receptor clusters in the hippocampus.
    explanation: >-
      The in vivo counterpart: removing Cdc42 itself does not reduce gephyrin
      or GABA-A receptor clusters.
  - reference: PMID:20345913
    reference_title: "PH-domain-driven targeting of collybistin but not Cdc42 activation is required for synaptic gephyrin clustering."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      In contrast, substitution of Cb II PH-domain residues essential for phosphoinositide binding abolished gephyrin recruitment to synaptic sites.
    explanation: >-
      Phosphoinositide binding by the PH domain is the required function.
  - reference: PMID:39374387
    reference_title: "Impaired axon initial segment structure and function in a model of ARHGEF9 developmental and epileptic encephalopathy."
    supports: SUPPORT
    evidence_source: IN_VITRO
    quote_role: BACKGROUND
    snippet: >-
      Functional studies with heterologous expression of ARHGEF9G55A showed aggregation of CB protein as well as loss of gephyrin and GABAAR clusters, suggesting that the G55A mutation might act in a dominant-negative manner
    explanation: >-
      Summarizes the earlier heterologous-expression result for the SH3-domain
      G55A variant and its possible dominant-negative action. The sentence is
      the paper's background summary of prior work.
  downstream:
  - target: Impaired Gephyrin Clustering at Inhibitory Postsynapses
    causal_link_type: DIRECT
    description: >-
      Collybistin is the factor that recruits gephyrin to the postsynaptic
      membrane; without functional collybistin, gephyrin is not clustered.
    evidence:
    - reference: PMID:30914922
      reference_title: "Mutation p.R356Q in the Collybistin Phosphoinositide Binding Site Is Associated With Mild Intellectual Disability."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        Expression of the PI3P-binding mutants CB3SH3- R356Q and CB3SH3- R356N/R357N in cultured hippocampal neurones revealed that the mutant proteins did not accumulate at inhibitory synapses, but instead resulted in a clear decrease in the overall number of synaptic gephyrin clusters compared to controls.
      explanation: >-
        A patient PH-domain variant reduces synaptic gephyrin clusters in
        cultured neurons, the specific step this edge asserts.
    - reference: PMID:31942680
      reference_title: "Clinical and Molecular Characterization of Three Novel ARHGEF9 Mutations in Patients with Developmental Delay and Epilepsy."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        In vitro studies confirmed that the two missense variants disrupted CB-mediated accumulation of gephyrin in submembrane microclusters.
      explanation: >-
        Two further patient missense variants (p.I294T, p.R357I) fail to cluster
        gephyrin.
  - target: Disinhibited mTORC1 Signaling
    causal_link_type: UNKNOWN
    hypothesis_groups:
    - collybistin_mtorc1_disinhibition
    description: >-
      Collybistin binds mTOR and restrains mTORC1 signalling; its loss is
      proposed to disinhibit the pathway. This is a second, gephyrin-independent
      consequence of loss of function.
    evidence:
    - reference: PMID:25898924
      reference_title: "Collybistin binds and inhibits mTORC1 signaling: a potential novel mechanism contributing to intellectual disability and autism."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        we describe that CB physically interacts with mTOR and inhibits mTORC1 signaling pathway and protein synthesis.
      explanation: >-
        Shown in iPSC-derived neural progenitors from a male with whole-gene
        deletion and in a heterologous system.

- name: Impaired Gephyrin Clustering at Inhibitory Postsynapses
  conforms_to: "epilepsy_excitation_inhibition_imbalance#Ion Channel and Synaptic Dysfunction"
  biological_scale: CELLULAR
  description: >-
    Gephyrin is the scaffold that anchors glycine receptors and major GABA-A
    receptor subtypes at inhibitory postsynapses. Collybistin, activated by the
    adhesion protein neuroligin-2 and anchored to the membrane through PI3P
    binding by its PH domain, is required to bring gephyrin to the membrane. In
    collybistin-deficient mice gephyrin fails to cluster at postsynaptic sites
    and accumulates as cytoplasmic aggregates, in a region-specific pattern
    (hippocampus and basolateral amygdala), and collybistin is needed both to
    form and to maintain these clusters.
  cell_types:
  - preferred_term: hippocampal pyramidal neuron
    term:
      id: CL:1001571
      label: hippocampal pyramidal neuron
  biological_processes:
  - preferred_term: gephyrin clustering involved in postsynaptic density assembly
    term:
      id: GO:0097116
      label: gephyrin clustering involved in postsynaptic density assembly
    modifier: DECREASED
  cellular_components:
  - preferred_term: inhibitory synapse
    term:
      id: GO:0060077
      label: inhibitory synapse
  locations:
  - preferred_term: hippocampal formation
    term:
      id: UBERON:0002421
      label: hippocampal formation
  - preferred_term: basolateral amygdala
    term:
      id: UBERON:0006107
      label: basolateral amygdaloid nuclear complex
  evidence:
  - reference: PMID:15215304
    reference_title: "The GDP-GTP exchange factor collybistin: an essential determinant of neuronal gephyrin clustering."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      We also demonstrate that gephyrin clustering in recombinant systems and cultured neurons requires both collybistin-gephyrin interactions and an intact collybistin pleckstrin homology domain.
    explanation: >-
      Establishes the dependence of gephyrin clustering on collybistin.
  - reference: PMID:18625319
    reference_title: "Collybistin is required for both the formation and maintenance of GABAergic postsynapses in the hippocampus."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Our data show that Cb is required for both the initial localization and maintenance of gephyrin and gephyrin-dependent GABA(A)Rs at inhibitory postsynaptic membrane specializations in the hippocampus.
    explanation: >-
      Conditional forebrain deletion in mice shows collybistin is needed for
      gephyrin clustering during synaptogenesis and afterwards.
  - reference: PMID:18625319
    reference_title: "Collybistin is required for both the formation and maintenance of GABAergic postsynapses in the hippocampus."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Deletion of Cb during embryonic development prevented gephyrin clustering during synaptogenesis and caused an accumulation of gephyrin aggregates in the cell body of CA1 pyramidal neurons.
    explanation: >-
      Gephyrin aggregates in the soma when collybistin is absent.
  - reference: PMID:19755106
    reference_title: "Neuroligin 2 drives postsynaptic assembly at perisomatic inhibitory synapses through gephyrin and collybistin."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Neuroligin 2 binds the scaffolding protein gephyrin through a conserved cytoplasmic motif and functions as a specific activator of collybistin, thus guiding membrane tethering of the inhibitory postsynaptic scaffold.
    explanation: >-
      Places collybistin in the neuroligin-2/gephyrin complex that assembles the
      inhibitory postsynaptic scaffold.
  downstream:
  - target: Loss of Postsynaptic GABA-A Receptor Clusters
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:17690689
      reference_title: "Impaired GABAergic transmission and altered hippocampal synaptic plasticity in collybistin-deficient mice."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        Together, our data indicate that Cb is essential for gephyrin-dependent clustering of a specific set of GABAA receptors, but not required for glycine receptor postsynaptic localization.
      explanation: >-
        In the knockout mouse, loss of collybistin removes gephyrin-dependent
        GABA-A receptor clusters.
    - reference: PMID:18615734
      reference_title: "A balanced chromosomal translocation disrupting ARHGEF9 is associated with epilepsy, anxiety, aggression, and mental retardation."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        Consistent with this finding, expression of truncated collybistin proteins in cultured neurons interferes with synaptic localization of endogenous gephyrin and GABA(A) receptors.
      explanation: >-
        The truncated collybistin produced by a patient's translocation allele
        disrupts synaptic gephyrin and GABA-A receptor localization in neurons.
  - target: Loss of Inhibitory Synapses at the Axon Initial Segment
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:39374387
      reference_title: "Impaired axon initial segment structure and function in a model of ARHGEF9 developmental and epileptic encephalopathy."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        In a mouse model carrying a patient-derived ARHGEF9 variant associated with severe disease, we observed aggregation of postsynaptic proteins and loss of functional inhibitory synapses at the axon initial segment (AIS)
      explanation: >-
        In the G55A knock-in mouse, postsynaptic proteins aggregate and
        axo-axonic inhibitory synapses at the AIS are lost.
  - target: Impaired Gephyrin-Dependent Glycine Receptor Clustering
    causal_link_type: UNKNOWN
    hypothesis_groups:
    - glycinergic_hyperekplexia
    description: >-
      Gephyrin also anchors glycine receptors, so a glycinergic defect was
      proposed to explain hyperekplexia in the first patient. The collybistin
      knockout mouse argues against a general requirement.
    evidence:
    - reference: PMID:15215304
      reference_title: "The GDP-GTP exchange factor collybistin: an essential determinant of neuronal gephyrin clustering."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        Glycine receptors (GlyRs) and specific subtypes of GABA(A) receptors are clustered at synapses by the multidomain protein gephyrin, which in turn is translocated to the cell membrane by the GDP-GTP exchange factor collybistin.
      explanation: >-
        The premise of the edge: glycine receptors share the gephyrin scaffold
        that collybistin delivers.
    - reference: PMID:17690689
      reference_title: "Impaired GABAergic transmission and altered hippocampal synaptic plasticity in collybistin-deficient mice."
      supports: REFUTE
      evidence_source: MODEL_ORGANISM
      snippet: >-
        Together, our data indicate that Cb is essential for gephyrin-dependent clustering of a specific set of GABAA receptors, but not required for glycine receptor postsynaptic localization.
      explanation: >-
        In the constitutive knockout, glycine receptor postsynaptic localization
        is preserved, which contradicts a general glycinergic defect.

- name: Loss of Postsynaptic GABA-A Receptor Clusters
  biological_scale: CELLULAR
  description: >-
    Without clustered gephyrin, the gephyrin-dependent GABA-A receptors (notably
    alpha2-containing receptors, which bind collybistin directly) are lost from
    postsynaptic sites. The loss is selective, affecting a specific set of
    receptors and synapse types rather than all GABAergic synapses.
  cell_types:
  - preferred_term: hippocampal pyramidal neuron
    term:
      id: CL:1001571
      label: hippocampal pyramidal neuron
  biological_processes:
  - preferred_term: gamma-aminobutyric acid receptor clustering
    term:
      id: GO:0097112
      label: gamma-aminobutyric acid receptor clustering
    modifier: DECREASED
  cellular_components:
  - preferred_term: GABA-ergic synapse
    term:
      id: GO:0098982
      label: GABA-ergic synapse
  evidence:
  - reference: PMID:17690689
    reference_title: "Impaired GABAergic transmission and altered hippocampal synaptic plasticity in collybistin-deficient mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Here we show that Cb-deficient mice display a region-specific loss of postsynaptic gephyrin and GABAA receptor clusters in the hippocampus and the basolateral amygdala.
    explanation: >-
      Direct demonstration in the knockout mouse.
  - reference: PMID:30087324
    reference_title: "Developmental seizures and mortality result from reducing GABA(A) receptor α2-subunit interaction with collybistin."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Using isothermal titration calorimetry and complementary methods we demonstrate an exclusive low micromolar binding of collybistin to the α2-subunit of GABAARs.
    explanation: >-
      Identifies the alpha2 subunit as the GABA-A receptor subunit that
      collybistin binds directly.
  downstream:
  - target: Reduced GABAergic Synaptic Inhibition
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:30087324
      reference_title: "Developmental seizures and mortality result from reducing GABA(A) receptor α2-subunit interaction with collybistin."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        The mutation results in loss of a distinct subset of inhibitory synapses and decreased amplitude of inhibitory synaptic currents.
      explanation: >-
        Disrupting only the collybistin-alpha2 interaction in mice removes a
        subset of inhibitory synapses and lowers inhibitory synaptic current.

- name: Loss of Inhibitory Synapses at the Axon Initial Segment
  biological_scale: CELLULAR
  description: >-
    In the Arhgef9 G55A knock-in mouse, which carries the SH3-domain variant of
    the first reported patient, postsynaptic proteins aggregate, functional
    axo-axonic inhibitory synapses at the axon initial segment are lost, AIS
    architecture is disrupted and action potential generation is altered.
  cell_types:
  - preferred_term: pyramidal neuron
    term:
      id: CL:0000598
      label: pyramidal neuron
  cellular_components:
  - preferred_term: axon initial segment
    term:
      id: GO:0043194
      label: axon initial segment
  evidence:
  - reference: PMID:39374387
    reference_title: "Impaired axon initial segment structure and function in a model of ARHGEF9 developmental and epileptic encephalopathy."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      we observed aggregation of postsynaptic proteins and loss of functional inhibitory synapses at the axon initial segment (AIS), altered axo-axonic synaptic inhibition, disrupted action potential generation, and complex seizure phenotypes consistent with clinical observations.
    explanation: >-
      Mouse knock-in of a patient-derived variant.
  downstream:
  - target: Cortical and Hippocampal Network Hyperexcitability
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:39374387
      reference_title: "Impaired axon initial segment structure and function in a model of ARHGEF9 developmental and epileptic encephalopathy."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        These results illustrate diverse roles of ARHGEF9 that converge on regulation of the structure and function of the AIS, thus revealing a pathological mechanism for ARHGEF9-associated DEE.
      explanation: >-
        The authors attribute the model's seizure phenotype to the AIS defect.

- name: Reduced GABAergic Synaptic Inhibition
  conforms_to: "epilepsy_excitation_inhibition_imbalance#Excitation-Inhibition Imbalance"
  biological_scale: CELLULAR
  description: >-
    Loss of synaptic GABA-A receptor clusters reduces dendritic GABAergic
    inhibition of principal neurons, shifting the balance toward excitation.
  cell_types:
  - preferred_term: hippocampal pyramidal neuron
    term:
      id: CL:1001571
      label: hippocampal pyramidal neuron
  biological_processes:
  - preferred_term: synaptic transmission, GABAergic
    term:
      id: GO:0051932
      label: synaptic transmission, GABAergic
    modifier: DECREASED
  - preferred_term: gamma-aminobutyric acid signaling pathway
    term:
      id: GO:0007214
      label: gamma-aminobutyric acid signaling pathway
    modifier: DECREASED
  evidence:
  - reference: PMID:17690689
    reference_title: "Impaired GABAergic transmission and altered hippocampal synaptic plasticity in collybistin-deficient mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Cb deficiency is accompanied by significant changes in hippocampal synaptic plasticity, due to reduced dendritic GABAergic inhibition.
    explanation: >-
      Reduced dendritic GABAergic inhibition in knockout hippocampus.
  downstream:
  - target: Cortical and Hippocampal Network Hyperexcitability
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:19236916
      reference_title: "Increased network excitability and impaired induction of long-term potentiation in the dentate gyrus of collybistin-deficient mice in vivo."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        In conclusion, our data provide the first evidence that Cb-deficiency leads to significant changes of GABAergic inhibition, network excitability and synaptic plasticity in vivo.
      explanation: >-
        In vivo recording links the inhibition deficit to increased network
        excitability.
  - target: Altered Hippocampal Synaptic Plasticity
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:17690689
      reference_title: "Impaired GABAergic transmission and altered hippocampal synaptic plasticity in collybistin-deficient mice."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        Cb deficiency is accompanied by significant changes in hippocampal synaptic plasticity, due to reduced dendritic GABAergic inhibition.
      explanation: >-
        The authors attribute the plasticity change to the reduced dendritic
        inhibition.

- name: Cortical and Hippocampal Network Hyperexcitability
  conforms_to: "epilepsy_excitation_inhibition_imbalance#Neuronal Hyperexcitability and Hypersynchrony"
  biological_scale: TISSUE
  description: >-
    Reduced synaptic and axo-axonic inhibition lowers the threshold for
    principal-cell firing. In collybistin-deficient mice the dentate gyrus shows
    a lower threshold for evoked population spikes, and the G55A knock-in mouse
    has spontaneous seizures of several types.
  locations:
  - preferred_term: hippocampal formation
    term:
      id: UBERON:0002421
      label: hippocampal formation
  evidence:
  - reference: PMID:19236916
    reference_title: "Increased network excitability and impaired induction of long-term potentiation in the dentate gyrus of collybistin-deficient mice in vivo."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      We found a decreased threshold for evoked population spikes of granule cells, indicating their increased excitability.
    explanation: >-
      In vivo measure of increased excitability in the knockout.
  downstream:
  - target: Seizures
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:39374387
      reference_title: "Impaired axon initial segment structure and function in a model of ARHGEF9 developmental and epileptic encephalopathy."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        The G55A variant also causes behavioral impairment and the generation of multiple seizure types including convulsive generalized tonic-clonic, tonic, spike-wave discharges, as well as interictal spikes.
      explanation: >-
        Seizures of several types in the patient-variant knock-in mouse.
  - target: Epileptic encephalopathy
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Where the hyperexcitable network produces frequent, drug-resistant
      seizures, the course is encephalopathic. The step from the mouse network
      finding to the human encephalopathy is inferred.
    evidence:
    - reference: PMID:35638461
      reference_title: "ARHGEF9 gene variant leads to developmental and epileptic encephalopathy: Genotypic phenotype analysis and treatment exploration."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        the clinical phenotype of epilepsy is often refractory and the prognosis is poor.
      explanation: >-
        The refractory, poor-prognosis epilepsy that defines the encephalopathic
        end of the spectrum in patients.

- name: Altered Hippocampal Synaptic Plasticity
  biological_scale: CELLULAR
  description: >-
    Collybistin-deficient mice show abnormal hippocampal long-term
    potentiation, together with increased anxiety and impaired spatial learning.
    The direction of the LTP change differs between preparations: enhanced LTP
    and reduced LTD in slices, but reduced LTP induction in the dentate gyrus
    in vivo. The link from this plasticity change to intellectual disability in
    patients is inferred from the mouse behaviour and has not been tested in
    humans.
  locations:
  - preferred_term: hippocampal formation
    term:
      id: UBERON:0002421
      label: hippocampal formation
  evidence:
  - reference: PMID:17690689
    reference_title: "Impaired GABAergic transmission and altered hippocampal synaptic plasticity in collybistin-deficient mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Long-term potentiation is enhanced, and long-term depression reduced, in Cb-deficient hippocampal slices.
    explanation: >-
      Slice electrophysiology in the knockout.
  - reference: PMID:19236916
    reference_title: "Increased network excitability and impaired induction of long-term potentiation in the dentate gyrus of collybistin-deficient mice in vivo."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      In addition, the induction of long-term potentiation (LTP) was reduced.
    explanation: >-
      In vivo LTP induction is reduced, in the opposite direction to the slice
      result; both are abnormal plasticity.
  downstream:
  - target: Intellectual disability
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:17690689
      reference_title: "Impaired GABAergic transmission and altered hippocampal synaptic plasticity in collybistin-deficient mice."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        Consistent with the anatomical and electrophysiological findings, the animals show increased levels of anxiety and impaired spatial learning.
      explanation: >-
        Impaired spatial learning in the knockout is the mouse correlate of the
        cognitive phenotype; the step to human intellectual disability is an
        inference.
  - target: Anxiety
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:17690689
      reference_title: "Impaired GABAergic transmission and altered hippocampal synaptic plasticity in collybistin-deficient mice."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        Consistent with the anatomical and electrophysiological findings, the animals show increased levels of anxiety and impaired spatial learning.
      explanation: >-
        Increased anxiety in the knockout, alongside the amygdala and
        hippocampal synaptic loss.

- name: Impaired Gephyrin-Dependent Glycine Receptor Clustering
  biological_scale: CELLULAR
  description: >-
    Proposed mechanism for hyperekplexia (exaggerated startle with neonatal
    stiffness), the hallmark of glycinergic synapse disorders, in the first
    reported patient. It is not established. In collybistin-knockout mice
    glycine receptors remain at postsynaptic sites, and hyperekplexia is absent
    in most later patients. On the other hand, mice carrying that patient's G55A
    variant do show an exaggerated acoustic startle, and the G55A protein
    aggregates with gephyrin and may act dominant-negatively, which a null
    allele would not. The node is kept so that the hyperekplexia phenotype is
    attached to its proposed mechanism and the uncertainty is visible.
  biological_processes:
  - preferred_term: glycine receptor clustering
    term:
      id: GO:0072579
      label: glycine receptor clustering
    modifier: DECREASED
  cellular_components:
  - preferred_term: glycinergic synapse
    term:
      id: GO:0098690
      label: glycinergic synapse
  evidence:
  - reference: PMID:15215304
    reference_title: "The GDP-GTP exchange factor collybistin: an essential determinant of neuronal gephyrin clustering."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The vital importance of collybistin for inhibitory synaptogenesis is underlined by the discovery of a mutation (G55A) in exon 2 of the human collybistin gene (ARHGEF9) in a patient with clinical symptoms of both hyperekplexia and epilepsy.
    explanation: >-
      The clinical observation (hyperekplexia) that motivated the glycinergic
      hypothesis.
  - reference: PMID:17690689
    reference_title: "Impaired GABAergic transmission and altered hippocampal synaptic plasticity in collybistin-deficient mice."
    supports: REFUTE
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Together, our data indicate that Cb is essential for gephyrin-dependent clustering of a specific set of GABAA receptors, but not required for glycine receptor postsynaptic localization.
    explanation: >-
      Glycine receptor localization is preserved in the knockout mouse.
  downstream:
  - target: Exaggerated startle response
    causal_link_type: UNKNOWN
    hypothesis_groups:
    - glycinergic_hyperekplexia

- name: Disinhibited mTORC1 Signaling
  biological_scale: CELLULAR
  description: >-
    Collybistin binds mTOR and inhibits mTORC1 signalling and protein synthesis
    in neural progenitor cells. In iPSC-derived neural progenitors from a male
    with a whole-gene deletion, loss of collybistin is proposed to disinhibit
    mTORC1, a pathway implicated in other forms of intellectual disability and
    autism. This has been shown only in cultured cells and its contribution to
    the patient phenotype is untested.
  biological_processes:
  - preferred_term: TOR signaling
    term:
      id: GO:0031929
      label: TOR signaling
    modifier: INCREASED
  evidence:
  - reference: PMID:25898924
    reference_title: "Collybistin binds and inhibits mTORC1 signaling: a potential novel mechanism contributing to intellectual disability and autism."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      These findings suggest that disinhibited mTORC1 signaling may also contribute to the pathological process in patients with loss-of-function variants in CB.
    explanation: >-
      The authors state the mTORC1 disinhibition model as a possible
      contributor.
  downstream:
  - target: Intellectual disability
    causal_link_type: UNKNOWN
    hypothesis_groups:
    - collybistin_mtorc1_disinhibition

mechanistic_hypotheses:
- hypothesis_group_id: glycinergic_hyperekplexia
  hypothesis_label: >-
    Hyperekplexia in ARHGEF9 disease reflects loss of gephyrin-dependent glycine
    receptor clustering
  status: ALTERNATIVE
  description: >-
    Proposed when the first patient, who had both hyperekplexia and epilepsy,
    was reported. It conflicts with the collybistin knockout mouse, in which
    glycine receptor localization is preserved, and with the rarity of
    hyperekplexia in later case series; it is consistent with the exaggerated
    startle of the G55A knock-in mouse. Whether the startle phenotype is
    glycinergic, specific to dominant-negative alleles such as G55A, or of
    another origin is unresolved.
  evidence:
  - reference: PMID:15215304
    reference_title: "The GDP-GTP exchange factor collybistin: an essential determinant of neuronal gephyrin clustering."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      This mislocalization of GABAA receptors, together with a corresponding expected deficit in glycine receptor trafficking in brain stem and spinal cord neurons, is likely to be causal for the clinical phenotype of the patient described above.
    explanation: >-
      The original authors' mechanistic interpretation of the G55A patient. The
      glycine receptor deficit is an expectation they draw from cultured-neuron
      data, not a measurement in brainstem or spinal cord.
  - reference: PMID:17690689
    reference_title: "Impaired GABAergic transmission and altered hippocampal synaptic plasticity in collybistin-deficient mice."
    supports: REFUTE
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Together, our data indicate that Cb is essential for gephyrin-dependent clustering of a specific set of GABAA receptors, but not required for glycine receptor postsynaptic localization.
    explanation: >-
      Contradicts a general requirement for collybistin at glycinergic synapses.
  - reference: PMID:33842008
    reference_title: "A proline-rich motif in the large intracellular loop of the glycine receptor α1 subunit interacts with the Pleckstrin homology domain of collybistin."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Our data suggest a novel interaction between α1 GlyR subunits and collybistin, which is physiologically relevant in vitro and in vivo and may contribute to postsynaptic anchoring of glycine receptors.
    explanation: >-
      A direct collybistin PH-domain interaction with the glycine receptor
      alpha1 subunit, a route by which collybistin could matter at glycinergic
      synapses; not tested in an ARHGEF9 disease model.
  - reference: PMID:39374387
    reference_title: "Impaired axon initial segment structure and function in a model of ARHGEF9 developmental and epileptic encephalopathy."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Consistent with ARHGEF9-DEE patients, Arhgef9G55A/Y mice were found to exhibit hyperekplexia and multiple seizure types
    explanation: >-
      The G55A knock-in reproduces the startle phenotype, consistent with an
      allele-specific mechanism; the paper does not show that the startle is
      glycinergic.
- hypothesis_group_id: collybistin_mtorc1_disinhibition
  hypothesis_label: >-
    Loss of collybistin disinhibits mTORC1 signalling, contributing to the
    neurodevelopmental phenotype
  status: EMERGING
  description: >-
    A gephyrin-independent consequence of collybistin loss, shown in patient
    iPSC-derived neural progenitors. Recorded as emerging because it rests on
    one cell-culture study and no in vivo or patient-level readout.
  evidence:
  - reference: PMID:25898924
    reference_title: "Collybistin binds and inhibits mTORC1 signaling: a potential novel mechanism contributing to intellectual disability and autism."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      These findings suggest that disinhibited mTORC1 signaling may also contribute to the pathological process in patients with loss-of-function variants in CB.
    explanation: >-
      Source of the hypothesis.

phenotypes:
- category: Neurologic
  name: Intellectual disability
  description: >-
    Present in every reported patient and the one constant feature. Severity
    ranges from mild to severe; in one 18-patient series ten were severe, seven
    moderate and one mild, and seven of the ten severe cases were nonverbal.
    Complete loss of the gene gives severe disability, milder missense variants
    moderate or mild disability, and males are more severely affected than
    females.
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:28589176
    reference_title: "ARHGEF9 disease: Phenotype clarification and genotype-phenotype correlation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All patients had ID ranging from mild (1) to moderate (7) to severe (10).
    explanation: >-
      18 of 18 patients had intellectual disability, supporting VERY_FREQUENT.
  - reference: PMID:28589176
    reference_title: "ARHGEF9 disease: Phenotype clarification and genotype-phenotype correlation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Intellectual disability was severe in most and moderate in patients with milder mutations.
    explanation: >-
      Severity tracks the allele.
  - reference: PMID:29130122
    reference_title: "ARHGEF9 mutations in epileptic encephalopathy/intellectual disability: toward understanding the mechanism underlying phenotypic variation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Further analysis revealed that all ARHGEF9 mutations were associated with intellectual disability, suggesting its critical role in psychomotor development.
    explanation: >-
      Independent literature analysis reaching the same conclusion.
  - reference: PMID:29130122
    reference_title: "ARHGEF9 mutations in epileptic encephalopathy/intellectual disability: toward understanding the mechanism underlying phenotypic variation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Male patients with ARHGEF9 mutations presented more severe phenotypes than female patients, which suggests a gene-dose effect and supports the pathogenic role of ARHGEF9 mutations.
    explanation: >-
      Supports the sex difference in severity.

- category: Neurologic
  name: Global developmental delay
  description: >-
    Delayed early milestones, often motor delay first, are the usual presenting
    problem in early childhood, either alone or together with seizures. Symptom
    onset in one series ranged from the first day of life to 7 years (median 9
    months).
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
    onset:
      onset_category: INFANTILE
  frequency: FREQUENT
  evidence:
  - reference: PMID:28589176
    reference_title: "ARHGEF9 disease: Phenotype clarification and genotype-phenotype correlation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The majority of patients (13) showed delayed early developmental milestones.
    explanation: >-
      13 of 18 (72%), the FREQUENT band.
  - reference: PMID:28589176
    reference_title: "ARHGEF9 disease: Phenotype clarification and genotype-phenotype correlation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Symptoms presented in early childhood with delayed motor development alone or in combination with seizures.
    explanation: >-
      Delayed motor development is the presenting feature.
  - reference: PMID:28589176
    reference_title: "ARHGEF9 disease: Phenotype clarification and genotype-phenotype correlation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Presenting symptoms: onset of symptoms occurred at a mean age of 15 months (median 9 months, range 1 day–7 years).
    explanation: >-
      Age at symptom onset.

- category: Neurologic
  name: Absent speech
  description: >-
    Severely affected patients are frequently nonverbal.
  phenotype_term:
    preferred_term: Absent speech
    term:
      id: HP:0001344
      label: Absent speech
  frequency: FREQUENT
  evidence:
  - reference: PMID:28589176
    reference_title: "ARHGEF9 disease: Phenotype clarification and genotype-phenotype correlation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Of the 10 patients with severe ID, 7 were nonverbal.
    explanation: >-
      7 of 18 patients (39%) were nonverbal, the FREQUENT band.

- category: Neurologic
  name: Developmental regression
  description: >-
    Developmental arrest and decline accompany uncontrolled seizures in the
    most severe, encephalopathic cases.
  phenotype_term:
    preferred_term: Developmental regression
    term:
      id: HP:0002376
      label: Developmental regression
  evidence:
  - reference: PMID:34851771
    reference_title: "A novel de novo hemizygous ARHGEF9 mutation associated with severe intellectual disability and epilepsy: a case report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Here, we report a boy with clinical symptoms of severe intellectual disability, epilepsy, and developmental delay and regression.
    explanation: >-
      Case report of regression in a boy with a de novo frameshift variant.
  - reference: ORPHA:163985
    reference_title: "Hyperekplexia-epilepsy syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Progressive epileptic encephalopathy, intellectual disability, and psychomotor development arrest, with subsequent decline, may be additionally associated.
    explanation: >-
      Orphanet definition includes developmental arrest and decline.

- category: Neurologic
  name: Seizures
  description: >-
    About 70% of patients in the largest clinical series have epilepsy. Onset
    was at a median of 12 months (mean 20 months; range 1 week to 7 years).
    Seizure types vary within and between patients; bilateral tonic-clonic and
    focal seizures are most common, and tonic and myoclonic seizures occur.
    Four of the 13 patients with epilepsy in that series were medically
    refractory, and most needed combination therapy. Seizure outcome can differ
    between affected brothers with the same variant. Missense variants confined
    to the PH domain (exon 9) have not been associated with epilepsy.
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
    onset:
      onset_category: INFANTILE
      min_age_years: 0.02
      max_age_years: 7
  frequency: FREQUENT
  evidence:
  - reference: PMID:28589176
    reference_title: "ARHGEF9 disease: Phenotype clarification and genotype-phenotype correlation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Thirteen patients had epilepsy with onset at a mean age of 20 months (median 12 months, range 1 week–7 years).
    explanation: >-
      13 of 18 patients (72%) had epilepsy, the FREQUENT band, and gives the
      onset range.
  - reference: PMID:28589176
    reference_title: "ARHGEF9 disease: Phenotype clarification and genotype-phenotype correlation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Four patients had medically refractory epilepsy, 4 showed 50% seizure reduction with antiepileptic drugs (AEDs), 1 showed seizure reduction of less than 50%, and 2 became completely seizure free without further AED treatment.
    explanation: >-
      Treatment response spans refractory to seizure-free.
  - reference: PMID:28589176
    reference_title: "ARHGEF9 disease: Phenotype clarification and genotype-phenotype correlation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Patients with mutations in exon 9 affecting the protein's PH domain did not develop epilepsy.
    explanation: >-
      Genotype-phenotype exception at the mild end of the spectrum.
  - reference: PMID:42216460
    reference_title: "Developmental and Epileptic Encephalopathy Due to a Novel ARHGEF9 Deletion Variant: Case Series of Two Siblings."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Notably, the two siblings exhibited a marked difference in outcomes: the elder brother achieved good seizure control with anti-epileptic drugs, while the proband, despite multidrug therapy and vagus nerve stimulation (VNS), exhibited a limited response and continued to experience frequent seizures.
    explanation: >-
      Intrafamilial variability in seizure outcome with the same hemizygous
      variant.

- category: Neurologic
  name: Epileptic encephalopathy
  description: >-
    The severe end of the spectrum, in which frequent drug-resistant seizures
    are accompanied by developmental arrest or decline. The first reported
    patient died at 4 years with a progressive epileptic encephalopathy.
  phenotype_term:
    preferred_term: Epileptic encephalopathy
    term:
      id: HP:0200134
      label: Epileptic encephalopathy
  evidence:
  - reference: PMID:35638461
    reference_title: "ARHGEF9 gene variant leads to developmental and epileptic encephalopathy: Genotypic phenotype analysis and treatment exploration."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We described five patients with developmental and epileptic encephalopathy caused by ARHGEF9 gene variants.
    explanation: >-
      Case series of DEE due to ARHGEF9.
  - reference: PMID:35638461
    reference_title: "ARHGEF9 gene variant leads to developmental and epileptic encephalopathy: Genotypic phenotype analysis and treatment exploration."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      the clinical phenotype of epilepsy is often refractory and the prognosis is poor.
    explanation: >-
      Refractory course and poor prognosis in the epileptic phenotype.
  - reference: PMID:15215304
    reference_title: "The GDP-GTP exchange factor collybistin: an essential determinant of neuronal gephyrin clustering."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Eventually, a progressive epileptic encephalopathy as well as hyperekplexia became evident and poly-drug treatment failed to provide adequate longterm seizure control.
    explanation: >-
      Clinical course of the index patient.
  - reference: PMID:15215304
    reference_title: "The GDP-GTP exchange factor collybistin: an essential determinant of neuronal gephyrin clustering."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      eventually leading to death at the age of 4 years and 4 months.
    explanation: >-
      Fatal outcome in the index patient.

- category: Neurologic
  name: Bilateral tonic-clonic seizures
  phenotype_term:
    preferred_term: Generalized tonic-clonic seizure
    term:
      id: HP:0002069
      label: Bilateral tonic-clonic seizure
  evidence:
  - reference: PMID:28589176
    reference_title: "ARHGEF9 disease: Phenotype clarification and genotype-phenotype correlation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Seizure types were variable, including generalized tonic-clonic (9), focal dyscognitive (5), focal (4), myoclonic (1), and tonic (2) seizures.
    explanation: >-
      Generalized tonic-clonic seizures in 9 of 13 patients with epilepsy.

- category: Neurologic
  name: Focal-onset seizures
  phenotype_term:
    preferred_term: Focal-onset seizure
    term:
      id: HP:0007359
      label: Focal-onset seizure
  evidence:
  - reference: PMID:28589176
    reference_title: "ARHGEF9 disease: Phenotype clarification and genotype-phenotype correlation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Seizure types were variable, including generalized tonic-clonic (9), focal dyscognitive (5), focal (4), myoclonic (1), and tonic (2) seizures.
    explanation: >-
      Focal and focal dyscognitive seizures are the second most common types.
  - reference: PMID:28620718
    reference_title: "The phenotypic spectrum of ARHGEF9 includes intellectual disability, focal epilepsy and febrile seizures."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Three developed afebrile seizures between age 7-17 years. Three showed focal seizure semiology. None had hyperekplexia.
    explanation: >-
      Focal epilepsy with later onset in a family with a hemizygous missense
      variant.

- category: Neurologic
  name: Tonic seizures
  description: >-
    In the first reported patient, tonic seizures began in the neonatal weeks
    and were provoked by touch.
  phenotype_term:
    preferred_term: Tonic seizure
    term:
      id: HP:0032792
      label: Tonic seizure
  evidence:
  - reference: ORPHA:163985
    reference_title: "Hyperekplexia-epilepsy syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      followed by the development of early-onset, frequently refractory, tonic or myoclonic seizures
    explanation: >-
      Orphanet definition names tonic and myoclonic seizures.
  - reference: PMID:15215304
    reference_title: "The GDP-GTP exchange factor collybistin: an essential determinant of neuronal gephyrin clustering."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      During the following weeks, the child developed tonic seizures that were provoked by tactile stimulation.
    explanation: >-
      Neonatal-period tonic seizures in the index patient.
  - reference: PMID:28589176
    reference_title: "ARHGEF9 disease: Phenotype clarification and genotype-phenotype correlation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Seizure types were variable, including generalized tonic-clonic (9), focal dyscognitive (5), focal (4), myoclonic (1), and tonic (2) seizures.
    explanation: >-
      Tonic seizures in 2 of 13 patients with epilepsy.

- category: Neurologic
  name: Febrile seizures
  description: >-
    Febrile seizures from age 2-3 years, later followed by afebrile focal
    seizures, were the epileptic phenotype in all four affected brothers of one
    family, none of whom had hyperekplexia.
  phenotype_term:
    preferred_term: Febrile seizure
    term:
      id: HP:0002373
      label: Febrile seizure (within the age range of 3 months to 6 years)
  evidence:
  - reference: PMID:28620718
    reference_title: "The phenotypic spectrum of ARHGEF9 includes intellectual disability, focal epilepsy and febrile seizures."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All affected male siblings had febrile seizures from age 2-3 years and intellectual disability.
    explanation: >-
      Febrile seizures in four hemizygous brothers.

- category: Neurologic
  name: Exaggerated startle response
  description: >-
    Hyperekplexia, the exaggerated startle to sudden stimuli that gives the
    disorder its older name, was a presenting feature of the first patient,
    together with neonatal stiffness; video-EEG showed that his seizures were
    both hyperekplectic and epileptic. It has been uncommon since: one of 18
    patients in a later series presented with it, and several reports note its
    absence.
  phenotype_term:
    preferred_term: Hyperekplexia
    term:
      id: HP:0002267
      label: Exaggerated startle response
    onset:
      onset_category: NEONATAL
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:15215304
    reference_title: "The GDP-GTP exchange factor collybistin: an essential determinant of neuronal gephyrin clustering."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      EEG monitoring coupled with ambulatory video revealed that the seizures were both hyperekplectic and epileptic in origin.
    explanation: >-
      The index patient.
  - reference: PMID:28589176
    reference_title: "ARHGEF9 disease: Phenotype clarification and genotype-phenotype correlation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      One patient presented with hyperekplexia and seizures shortly after birth
    explanation: >-
      1 of 18 patients (about 6%), the OCCASIONAL band.
  - reference: PMID:18615734
    reference_title: "A balanced chromosomal translocation disrupting ARHGEF9 is associated with epilepsy, anxiety, aggression, and mental retardation."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We report the identification of a balanced chromosomal translocation in a female patient presenting with a disturbed sleep-wake cycle, late-onset epileptic seizures, increased anxiety, aggressive behavior, and mental retardation, but not hyperekplexia.
    explanation: >-
      Documents absence of hyperekplexia in an affected female, showing it is
      not a constant feature.

- category: Neurologic
  name: Neonatal hypertonia
  description: >-
    Muscle stiffness immediately after birth in the index patient; Orphanet
    describes neonatal hypertonia evolving to hypotonia.
  phenotype_term:
    preferred_term: Neonatal hypertonia
    term:
      id: HP:0001276
      label: Hypertonia
    onset:
      onset_category: NEONATAL
  evidence:
  - reference: ORPHA:163985
    reference_title: "Hyperekplexia-epilepsy syndrome"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      characterized by neonatal hypertonia which evolves to hypotonia and an exaggerated startle response
    explanation: >-
      Orphanet definition of the hyperekplexia-epilepsy presentation.
  - reference: PMID:15215304
    reference_title: "The GDP-GTP exchange factor collybistin: an essential determinant of neuronal gephyrin clustering."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Immediately after delivery, cyanosis and muscular stiffness
    explanation: >-
      Clinical description of the index patient at birth.

- category: Neurologic
  name: Sensory hyperarousal
  description: >-
    Sensory hyperarousal was the presenting feature, with intellectual
    disability, of a female whose ARHGEF9 allele was disrupted by an X
    inversion.
  phenotype_term:
    preferred_term: Sensory hyperarousal
    term:
      id: HP:5200058
      label: Sensory hypersensitivity
  evidence:
  - reference: PMID:17893116
    reference_title: "ARHGEF9 disruption in a female patient is associated with X linked mental retardation and sensory hyperarousal."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We identified a female patient with mental retardation and sensory hyperarousal.
    explanation: >-
      Case report of the phenotype.

- category: Neurologic
  name: EEG abnormality
  description: >-
    Epileptiform discharges may be generalized, bilateral, multifocal or focal,
    and the EEG can be normal. One patient with polymicrogyria had continuous
    spike-and-wave in slow-wave sleep. Abnormal baseline EEG is a recurring
    finding in literature reviews.
  phenotype_term:
    preferred_term: EEG abnormality
    term:
      id: HP:0002353
      label: EEG abnormality
  evidence:
  - reference: PMID:28589176
    reference_title: "ARHGEF9 disease: Phenotype clarification and genotype-phenotype correlation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      EEG findings were available for 11 of the 13 patients and showed generalized (3), bilateral (1), multifocal (1), and focal (1) epileptiform discharges and were normal in 2 patients.
    explanation: >-
      EEG findings in the 18-patient series.
  - reference: PMID:28589176
    reference_title: "ARHGEF9 disease: Phenotype clarification and genotype-phenotype correlation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      One patient with polymicrogyria showed continuous spike-and-wave discharges in slow-wave sleep.
    explanation: >-
      Continuous spike-and-wave in sleep in one patient.
  - reference: PMID:35169261
    reference_title: "Human ARHGEF9 intellectual disability syndrome is phenocopied by a mutation that disrupts collybistin binding to the GABA(A) receptor α2 subunit."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Evaluation of 41 ARHGEF9 patient reports shows ubiquitous inclusion of ID, along with other frequently reported symptoms of epilepsy, abnormal baseline EEG activity, behavioral symptoms, and sleep disturbances.
    explanation: >-
      Literature review naming abnormal baseline EEG as a frequently reported
      feature.

- category: Behavioral
  name: Autistic behavior
  description: >-
    Autistic features occur in males and are the main presentation of some
    females with de novo intragenic deletions and mild intellectual disability.
  phenotype_term:
    preferred_term: Autistic behavior
    term:
      id: HP:0000729
      label: Autistic behavior
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:28589176
    reference_title: "ARHGEF9 disease: Phenotype clarification and genotype-phenotype correlation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Autistic features were reported in 4 patients. Five patients had hyperactivity.
    explanation: >-
      4 of 18 (22%), the OCCASIONAL band.
  - reference: PMID:30048823
    reference_title: "Autism spectrum disorder in females with ARHGEF9 alterations and a random pattern of X chromosome inactivation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We report two unrelated females with autism and mild intellectual disability.
    explanation: >-
      Autism in two females with de novo ARHGEF9 deletions.
  - reference: PMID:27238888
    reference_title: "Xq11.1-11.2 deletion involving ARHGEF9 in a girl with autism spectrum disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We report an 8-year-old female with autism spectrum disorder (ASD), intellectual disability and speech delay who was found to carry a de novo 82 kb deletion of chromosome Xq11.1-11.2 involving the ARHGEF9 gene on chromosomal microarray.
    explanation: >-
      A further girl with autism and a de novo deletion including ARHGEF9.

- category: Behavioral
  name: Hyperactivity
  phenotype_term:
    preferred_term: Hyperactivity
    term:
      id: HP:0000752
      label: Hyperactivity
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:28589176
    reference_title: "ARHGEF9 disease: Phenotype clarification and genotype-phenotype correlation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Autistic features were reported in 4 patients. Five patients had hyperactivity.
    explanation: >-
      5 of 18 (28%), the OCCASIONAL band.

- category: Behavioral
  name: Anxiety
  phenotype_term:
    preferred_term: Anxiety
    term:
      id: HP:0000739
      label: Anxiety
  evidence:
  - reference: PMID:18615734
    reference_title: "A balanced chromosomal translocation disrupting ARHGEF9 is associated with epilepsy, anxiety, aggression, and mental retardation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We report the identification of a balanced chromosomal translocation in a female patient presenting with a disturbed sleep-wake cycle, late-onset epileptic seizures, increased anxiety, aggressive behavior, and mental retardation, but not hyperekplexia.
    explanation: >-
      Increased anxiety in a female with a gene-disrupting translocation.

- category: Behavioral
  name: Aggressive behavior
  phenotype_term:
    preferred_term: Aggressive behavior
    term:
      id: HP:0000718
      label: Aggressive behavior
  evidence:
  - reference: PMID:18615734
    reference_title: "A balanced chromosomal translocation disrupting ARHGEF9 is associated with epilepsy, anxiety, aggression, and mental retardation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We report the identification of a balanced chromosomal translocation in a female patient presenting with a disturbed sleep-wake cycle, late-onset epileptic seizures, increased anxiety, aggressive behavior, and mental retardation, but not hyperekplexia.
    explanation: >-
      Aggressive behaviour in the same patient.
  - reference: PMID:28589176
    reference_title: "ARHGEF9 disease: Phenotype clarification and genotype-phenotype correlation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Additional features included sleep disorder (4), ataxic gait (1), aggressive behavior (2)
    explanation: >-
      Aggressive behaviour in 2 of 18 patients.

- category: Behavioral
  name: Sleep disturbance
  phenotype_term:
    preferred_term: Sleep disturbance
    term:
      id: HP:0002360
      label: Sleep disturbance
  evidence:
  - reference: PMID:28589176
    reference_title: "ARHGEF9 disease: Phenotype clarification and genotype-phenotype correlation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Additional features included sleep disorder (4), ataxic gait (1), aggressive behavior (2)
    explanation: >-
      Sleep disorder in 4 of 18 patients.
  - reference: PMID:35169261
    reference_title: "Human ARHGEF9 intellectual disability syndrome is phenocopied by a mutation that disrupts collybistin binding to the GABA(A) receptor α2 subunit."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Evaluation of 41 ARHGEF9 patient reports shows ubiquitous inclusion of ID, along with other frequently reported symptoms of epilepsy, abnormal baseline EEG activity, behavioral symptoms, and sleep disturbances.
    explanation: >-
      Sleep disturbance is among the frequently reported features in a
      41-report review.

- category: Craniofacial
  name: Large fleshy earlobes
  description: >-
    Part of the facial gestalt of the most severely affected males (severe
    intellectual disability and seizures), together with midface hypoplasia and
    prognathism. Patients with milder alleles do not show it.
  phenotype_term:
    preferred_term: Large fleshy earlobes
    term:
      id: HP:0009748
      label: Large earlobe
  evidence:
  - reference: PMID:28589176
    reference_title: "ARHGEF9 disease: Phenotype clarification and genotype-phenotype correlation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Facial dysmorphism, in particular, enlarged earlobes, midface hypoplasia, and prognathism appear to be a constant feature of the neurologically severely affected male patients.
    explanation: >-
      The facial gestalt in severely affected males.

- category: Craniofacial
  name: Midface retrusion
  phenotype_term:
    preferred_term: Midface hypoplasia
    term:
      id: HP:0011800
      label: Midface retrusion
  evidence:
  - reference: PMID:28589176
    reference_title: "ARHGEF9 disease: Phenotype clarification and genotype-phenotype correlation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Facial dysmorphism, in particular, enlarged earlobes, midface hypoplasia, and prognathism appear to be a constant feature of the neurologically severely affected male patients.
    explanation: >-
      Midface hypoplasia is part of the gestalt.

- category: Craniofacial
  name: Mandibular prognathia
  phenotype_term:
    preferred_term: Prognathism
    term:
      id: HP:0000303
      label: Mandibular prognathia
  evidence:
  - reference: PMID:28589176
    reference_title: "ARHGEF9 disease: Phenotype clarification and genotype-phenotype correlation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Facial dysmorphism, in particular, enlarged earlobes, midface hypoplasia, and prognathism appear to be a constant feature of the neurologically severely affected male patients.
    explanation: >-
      Prognathism is part of the gestalt.

- category: Craniofacial
  name: Macrocephaly
  description: >-
    Reported variably, in a family with the R338W missense variant and in a boy
    with a 1.3 Mb Xq11.11 deletion that included ARHGEF9 and other genes; not a
    consistent feature.
  phenotype_term:
    preferred_term: Macrocephaly
    term:
      id: HP:0000256
      label: Macrocephaly
  evidence:
  - reference: PMID:26834553
    reference_title: "Missense Mutation R338W in ARHGEF9 in a Family with X-linked Intellectual Disability with Variable Macrocephaly and Macro-Orchidism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We report the resolution of a large family (K8010) with NS-XLID, with variable macrocephaly and macro-orchidism.
    explanation: >-
      Variable macrocephaly segregating in one family.
  - reference: PMID:21626670
    reference_title: "De novo Xq11.11 microdeletion including ARHGEF9 in a boy with mental retardation, epilepsy, macrosomia, and dysmorphic features."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We report on a novel Xq11.11 microdeletion in a patient presenting with severe mental retardation (MR), focal epilepsy, tall stature, macrocephaly, and dysmorphism.
    explanation: >-
      Macrocephaly in a boy with a deletion; the deletion includes other genes,
      so attribution to ARHGEF9 is uncertain.

- category: Skeletal
  name: Fifth-finger clinodactyly
  phenotype_term:
    preferred_term: Clinodactyly of the 5th finger
    term:
      id: HP:0004209
      label: Clinodactyly of the 5th finger
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:28589176
    reference_title: "ARHGEF9 disease: Phenotype clarification and genotype-phenotype correlation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Two patients showed 5-digit clinodactyly.
    explanation: >-
      2 of 18 patients (11%), the OCCASIONAL band.

- category: Skeletal
  name: Pectus excavatum
  phenotype_term:
    preferred_term: Pectus excavatum
    term:
      id: HP:0000767
      label: Pectus excavatum
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:28589176
    reference_title: "ARHGEF9 disease: Phenotype clarification and genotype-phenotype correlation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      fetal finger and toe pads (2), pigmentation abnormalities (2), pectus excavatum (2)
    explanation: >-
      2 of 18 patients (11%), the OCCASIONAL band.

- category: Dermatologic
  name: Persistent fetal finger and toe pads
  phenotype_term:
    preferred_term: Fetal finger and toe pads
    term:
      id: HP:0001212
      label: Prominent fingertip pads
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:28589176
    reference_title: "ARHGEF9 disease: Phenotype clarification and genotype-phenotype correlation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      fetal finger and toe pads (2), pigmentation abnormalities (2), pectus excavatum (2)
    explanation: >-
      2 of 18 patients (11%), the OCCASIONAL band.

genetic:
- name: ARHGEF9
  gene_term:
    preferred_term: ARHGEF9
    term:
      id: hgnc:14561
      label: ARHGEF9
  association: >-
    ARHGEF9 (Xq11.1) encodes collybistin. ClinGen classifies ARHGEF9 as
    Definitive for X-linked complex neurodevelopmental disorder, the broader
    MONDO grouping under which DEE8 sits. Pathogenic alleles include missense,
    nonsense, frameshift and splice variants, intragenic and whole-gene
    deletions, and balanced rearrangements disrupting the gene. Missense
    variants confined to the PH domain are associated with intellectual
    disability without epilepsy, whereas complete loss of the gene and severe
    DH-domain variants are associated with severe epilepsy.
  relationship_type: CAUSATIVE
  evidence:
  - reference: CGGV:assertion_9305fb2c-6cdf-492d-9dd0-8b03dd4fab1c-2024-05-23T100000.000Z
    reference_title: "ARHGEF9 / X-linked complex neurodevelopmental disorder (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      ARHGEF9 | HGNC:14561 | X-linked complex neurodevelopmental disorder | MONDO:0100148 | XL | Definitive
    explanation: >-
      ClinGen gene-disease validity: Definitive (Intellectual Disability and
      Autism GCEP, SOP10, 2024-05-23). The assertion is against the broader
      MONDO:0100148 grouping, not against MONDO:0010375 itself.
  - reference: CGGV:assertion_9305fb2c-6cdf-492d-9dd0-8b03dd4fab1c-2024-05-23T100000.000Z
    reference_title: "ARHGEF9 / X-linked complex neurodevelopmental disorder (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The molecular spectrum of ARHGEF9 variants include missense, copy number variants, frameshift, nonsense, and structural X-chromosome abnormalities
    explanation: >-
      ClinGen summary of the allelic spectrum.
  - reference: PMID:29130122
    reference_title: "ARHGEF9 mutations in epileptic encephalopathy/intellectual disability: toward understanding the mechanism underlying phenotypic variation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Three missense mutations in the PH domain were not associated with epilepsy, suggesting that the co-occurrence of epilepsy depends on the affected functional domains. Missense mutations with severe molecular alteration in the DH domain, or located in the DH-gephyrin binding region, or adjacent to the SH3-NL2 binding site were associated with severe epilepsy
    explanation: >-
      Domain-based genotype-phenotype correlation.
  - reference: PMID:28589176
    reference_title: "ARHGEF9 disease: Phenotype clarification and genotype-phenotype correlation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Loss of only the protein's PH domain function is associated with the absence of epilepsy.
    explanation: >-
      Same correlation from the 18-patient series.

diagnosis:
- name: Chromosomal microarray
  description: >-
    Diagnosis is molecular. Because a large share of reported ARHGEF9 disease
    is due to deletions and chromosomal disruptions (7 of 18 patients in the
    largest series had chromosomal disruptions), chromosomal microarray is
    recommended as the first-line test. In a female, a balanced rearrangement
    disrupting the gene will not be seen on microarray and needs karyotype or
    breakpoint mapping.
  diagnosis_term:
    preferred_term: chromosomal microarray
    term:
      id: NCIT:C198497
      label: Array-based Comparative Genomic Hybridization
  evidence:
  - reference: PMID:28589176
    reference_title: "ARHGEF9 disease: Phenotype clarification and genotype-phenotype correlation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Therefore, the diagnostic approach in candidate patients still requires chromosomal microarray testing as the first-line genetic testing because of the substantial diagnostic yield and low relative cost, followed by a gene panel or whole-exome sequencing approach as second tier.
    explanation: >-
      Recommendation from the 18-patient series.
  - reference: PMID:28589176
    reference_title: "ARHGEF9 disease: Phenotype clarification and genotype-phenotype correlation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A total of 18 patients (including 5 females) were identified. Six had de novo, 5 had maternally inherited mutations, and 7 had chromosomal disruptions.
    explanation: >-
      The chromosomal-disruption fraction behind the first-line recommendation.
- name: Gene panel or exome sequencing
  description: >-
    Second-tier testing for sequence variants (missense, nonsense,
    frameshift, splice) by an epilepsy or intellectual-disability gene panel
    or by exome sequencing. Parental testing distinguishes de novo from
    maternally inherited variants, which matters for counselling the mother.
  diagnosis_term:
    preferred_term: gene panel or whole-exome sequencing
    term:
      id: NCIT:C15709
      label: Genetic Testing
  evidence:
  - reference: PMID:28589176
    reference_title: "ARHGEF9 disease: Phenotype clarification and genotype-phenotype correlation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Therefore, the diagnostic approach in candidate patients still requires chromosomal microarray testing as the first-line genetic testing because of the substantial diagnostic yield and low relative cost, followed by a gene panel or whole-exome sequencing approach as second tier.
    explanation: >-
      Panel or exome sequencing is the recommended second tier.
- name: Electroencephalography
  description: >-
    EEG documents epileptiform activity and the encephalopathic background. It
    is not specific for ARHGEF9 disease; findings range from normal to
    generalized, multifocal or focal discharges, and continuous spike-and-wave
    in sleep was seen in one patient.
  diagnosis_term:
    preferred_term: Electroencephalography
    term:
      id: NCIT:C38054
      label: Electroencephalography
  evidence:
  - reference: PMID:28589176
    reference_title: "ARHGEF9 disease: Phenotype clarification and genotype-phenotype correlation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      EEG findings were available for 11 of the 13 patients and showed generalized (3), bilateral (1), multifocal (1), and focal (1) epileptiform discharges and were normal in 2 patients.
    explanation: >-
      Range of EEG findings in the 18-patient series.
  - reference: PMID:15215304
    reference_title: "The GDP-GTP exchange factor collybistin: an essential determinant of neuronal gephyrin clustering."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      EEG monitoring coupled with ambulatory video revealed that the seizures were both hyperekplectic and epileptic in origin.
    explanation: >-
      Video-EEG separated hyperekplectic from epileptic events in the index
      patient.

treatments:
- name: Antiseizure medication
  description: >-
    There is no disease-specific therapy. Seizures are treated with standard
    antiseizure medications, usually in combination, and response ranges from
    seizure freedom to drug resistance. Valproic acid and levetiracetam were
    each reported effective in individual patients in one small series, which is
    case-level evidence rather than a comparative result.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: valproic acid
      term:
        id: CHEBI:39867
        label: valproic acid
    - preferred_term: levetiracetam
      term:
        id: CHEBI:6437
        label: levetiracetam
  therapeutic_modality: SMALL_MOLECULE
  target_phenotypes:
  - preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:35638461
    reference_title: "ARHGEF9 gene variant leads to developmental and epileptic encephalopathy: Genotypic phenotype analysis and treatment exploration."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Among them, the antiepileptic treatment of valproic acid and levetiracetam was effective in two cases individually.
    explanation: >-
      Case-level report of response to valproic acid and levetiracetam.
  - reference: PMID:28589176
    reference_title: "ARHGEF9 disease: Phenotype clarification and genotype-phenotype correlation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      AEDs consisted mainly of combination therapy (10); only 1 patient was on monotherapy (1).
    explanation: >-
      Most treated patients need polytherapy.

- name: Clonazepam
  description: >-
    Clonazepam is the usual symptomatic treatment for hyperekplexia. In the one
    ARHGEF9 patient in whom its effect on hyperekplexia is reported, the index
    G55A patient, it was unsuccessful. That is a single case, so it records a
    failure rather than establishing that clonazepam does not work in ARHGEF9
    disease.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: clonazepam
      term:
        id: CHEBI:3756
        label: clonazepam
  therapeutic_modality: SMALL_MOLECULE
  target_phenotypes:
  - preferred_term: Exaggerated startle response
    term:
      id: HP:0002267
      label: Exaggerated startle response
  evidence:
  - reference: PMID:15215304
    reference_title: "The GDP-GTP exchange factor collybistin: an essential determinant of neuronal gephyrin clustering."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      At 4 months of age, a diagnosis of hyperekplexia was made, but therapy with clonazepam was unsuccessful.
    explanation: >-
      Clonazepam failed for hyperekplexia in the index patient.

animal_models:
- name: Arhgef9 constitutive knockout mouse
  species: Mus musculus
  genotype: Arhgef9 null (collybistin-deficient)
  description: >-
    Constitutive collybistin knockout. Gephyrin and GABA-A receptor clusters are
    lost in a region-specific way from hippocampus and basolateral amygdala,
    dendritic GABAergic inhibition is reduced, hippocampal plasticity is
    abnormal, dentate gyrus excitability is increased in vivo, and the animals
    show increased anxiety and impaired spatial learning. Glycine receptor
    localization is preserved. Conditional forebrain deletion shows collybistin
    is needed both to form and to maintain these synapses.
  genes:
  - preferred_term: ARHGEF9
    term:
      id: hgnc:14561
      label: ARHGEF9
  publication: PMID:17690689
  modeled_mechanisms:
  - target: Loss of Postsynaptic GABA-A Receptor Clusters
    relationship: RECAPITULATES
    fidelity: MODERATE
    limitations: >-
      Mouse null allele; the loss is region-specific in the mouse, and the human
      brain distribution of the defect is unknown.
    evidence:
    - reference: PMID:17690689
      reference_title: "Impaired GABAergic transmission and altered hippocampal synaptic plasticity in collybistin-deficient mice."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        Here we show that Cb-deficient mice display a region-specific loss of postsynaptic gephyrin and GABAA receptor clusters in the hippocampus and the basolateral amygdala.
      explanation: >-
        Shows the model reproduces the receptor-clustering node.
  - target: Impaired Gephyrin-Dependent Glycine Receptor Clustering
    relationship: FAILS_TO_RECAPITULATE
    fidelity: UNKNOWN
    limitations: >-
      Glycine receptor postsynaptic localization is preserved in the null mouse,
      so it does not model a glycinergic basis for the hyperekplexia seen in the
      SH3-domain G55A patient; a dominant-negative allele effect would not be
      captured by a null.
    evidence:
    - reference: PMID:17690689
      reference_title: "Impaired GABAergic transmission and altered hippocampal synaptic plasticity in collybistin-deficient mice."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        Together, our data indicate that Cb is essential for gephyrin-dependent clustering of a specific set of GABAA receptors, but not required for glycine receptor postsynaptic localization.
      explanation: >-
        The negative result on glycine receptors.
  - target: Cortical and Hippocampal Network Hyperexcitability
    relationship: PARTIALLY_RECAPITULATES
    fidelity: MODERATE
    limitations: >-
      Shows increased evoked excitability of dentate granule cells in vivo; the
      constitutive-knockout papers cited here do not report spontaneous
      seizures.
    evidence:
    - reference: PMID:19236916
      reference_title: "Increased network excitability and impaired induction of long-term potentiation in the dentate gyrus of collybistin-deficient mice in vivo."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        We found a decreased threshold for evoked population spikes of granule cells, indicating their increased excitability.
      explanation: >-
        Evoked network hyperexcitability in vivo.
  evidence:
  - reference: PMID:17690689
    reference_title: "Impaired GABAergic transmission and altered hippocampal synaptic plasticity in collybistin-deficient mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Consistent with the anatomical and electrophysiological findings, the animals show increased levels of anxiety and impaired spatial learning.
    explanation: >-
      Behavioural phenotype of the model.

- name: Arhgef9 G55A knock-in mouse
  species: Mus musculus
  genotype: Arhgef9 G55A/Y (hemizygous knock-in of the index-patient SH3-domain variant)
  description: >-
    Knock-in of the G55A variant found in the first reported patient, who had
    hyperekplexia and a fatal epileptic encephalopathy. Postsynaptic proteins
    aggregate, inhibitory synapses at the axon initial segment are lost, action
    potential generation is disrupted, and the mice have an exaggerated acoustic
    startle and generalized tonic-clonic, tonic and spike-wave seizures.
  genes:
  - preferred_term: ARHGEF9
    term:
      id: hgnc:14561
      label: ARHGEF9
  publication: PMID:39374387
  modeled_mechanisms:
  - target: Loss of Inhibitory Synapses at the Axon Initial Segment
    relationship: RECAPITULATES
    fidelity: MODERATE
    limitations: >-
      Models one severe missense allele; whether the AIS defect generalizes to
      null or PH-domain alleles is not tested, and AIS pathology has not been
      examined in patient tissue.
    evidence:
    - reference: PMID:39374387
      reference_title: "Impaired axon initial segment structure and function in a model of ARHGEF9 developmental and epileptic encephalopathy."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        In a mouse model carrying a patient-derived ARHGEF9 variant associated with severe disease, we observed aggregation of postsynaptic proteins and loss of functional inhibitory synapses at the axon initial segment (AIS)
      explanation: >-
        Direct observation in the model.
  evidence:
  - reference: PMID:39374387
    reference_title: "Impaired axon initial segment structure and function in a model of ARHGEF9 developmental and epileptic encephalopathy."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      The G55A variant also causes behavioral impairment and the generation of multiple seizure types including convulsive generalized tonic-clonic, tonic, spike-wave discharges, as well as interictal spikes.
    explanation: >-
      Seizure phenotype of the model.
  - reference: PMID:39374387
    reference_title: "Impaired axon initial segment structure and function in a model of ARHGEF9 developmental and epileptic encephalopathy."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Consistent with ARHGEF9-DEE patients, Arhgef9G55A/Y mice were found to exhibit hyperekplexia and multiple seizure types
    explanation: >-
      Startle phenotype of the model.

- name: Gabra2-1 mouse (collybistin-alpha2 binding mutant)
  species: Mus musculus
  genotype: Gabra2-1 (collybistin-binding motif of the GABA-A receptor alpha2 subunit replaced by the alpha1 gephyrin-binding motif)
  description: >-
    Not an Arhgef9 allele. The collybistin-binding motif of the GABA-A receptor
    alpha2 subunit is replaced, which down-regulates collybistin, particularly
    at cholecystokinin basket-cell synapses. The mice have developmental
    seizures with early mortality, anxiety, hyperactivity, memory deficits and
    reduced social preference, which the authors present as a phenocopy of
    human ARHGEF9 disease. EEG and anxiety phenotypes were ameliorated by the
    alpha2/alpha3-selective positive modulator AZD7325.
  genes:
  - preferred_term: GABRA2
    term:
      id: hgnc:4076
      label: GABRA2
  publication: PMID:30087324
  modeled_mechanisms:
  - target: Reduced GABAergic Synaptic Inhibition
    relationship: PERTURBS
    fidelity: MODERATE
    limitations: >-
      Perturbs one collybistin-receptor interaction rather than collybistin
      itself; it isolates the alpha2 arm of the mechanism and cannot model
      gephyrin-wide or mTORC1 effects.
    evidence:
    - reference: PMID:30087324
      reference_title: "Developmental seizures and mortality result from reducing GABA(A) receptor α2-subunit interaction with collybistin."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        The mutation results in loss of a distinct subset of inhibitory synapses and decreased amplitude of inhibitory synaptic currents.
      explanation: >-
        Reduced inhibitory synaptic current in the model.
  evidence:
  - reference: PMID:35169261
    reference_title: "Human ARHGEF9 intellectual disability syndrome is phenocopied by a mutation that disrupts collybistin binding to the GABA(A) receptor α2 subunit."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      The Gabra2-1 mutation causes a strong downregulation of Cb expression, particularly at cholecystokinin basket cell inhibitory synapses.
    explanation: >-
      Collybistin loss at a defined synapse type in the model.
  - reference: PMID:35169261
    reference_title: "Human ARHGEF9 intellectual disability syndrome is phenocopied by a mutation that disrupts collybistin binding to the GABA(A) receptor α2 subunit."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Gabra2-1 mice have deficits in working and recognition memory, as well as hyperactivity, anxiety, and reduced social preference, recapitulating the frequently reported features of ARHGEF9 patients.
    explanation: >-
      Behavioural phenocopy.
  - reference: PMID:35169261
    reference_title: "Human ARHGEF9 intellectual disability syndrome is phenocopied by a mutation that disrupts collybistin binding to the GABA(A) receptor α2 subunit."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Gabra2-1 mice also have spontaneous seizures during postnatal development which can lead to mortality, and baseline abnormalities in low-frequency wavelengths of the EEG.
    explanation: >-
      Developmental seizures and mortality in the phenocopy model.
  - reference: PMID:30087324
    reference_title: "Developmental seizures and mortality result from reducing GABA(A) receptor α2-subunit interaction with collybistin."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Surviving Gabra2-1 mice show anxiety and elevations in electroencephalogram δ power, which are ameliorated by treatment with the α2/α3-selective positive modulator, AZD7325.
    explanation: >-
      Pharmacological rescue in the model; no human data.

discussions:
- discussion_id: controversy_arhgef9_female_expression
  prompt: >-
    Are ARHGEF9 loss-of-function alleles X-linked dominant, or is disease in
    heterozygous females explained by skewed X-inactivation in brain that blood
    does not show?
  kind: CONTROVERSY
  status: OPEN
  attaches_to:
  - inheritance#X-linked
  rationale: >-
    The early affected females all carried chromosomal rearrangements with
    strongly skewed X-inactivation in favour of the abnormal X. Later females
    with de novo intragenic deletions or single-nucleotide variants had random
    X-inactivation in blood, prompting a proposal that loss-of-function alleles
    behave as X-linked dominant. Blood X-inactivation is an imperfect proxy for
    brain, and variants transmitted by mildly affected or unaffected mothers
    complicate the picture. The answer changes recurrence counselling for the
    mothers and sisters of affected boys.
  evidence:
  - reference: PMID:33600053
    reference_title: "Loss-of-function variants in ARHGEF9 are associated with an X-linked intellectual disability dominant disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Up to now, sequence variants and gross deletions have been identified in males, while only chromosomal aberrations have been reported in affected females who showed a skewed pattern of X-chromosome inactivation (XCI), suggesting an X-linked recessive (XLR) disorder.
    explanation: >-
      States the earlier recessive interpretation that the paper then
      challenges.
  - reference: PMID:32939676
    reference_title: "De novo ARHGEF9 missense variants associated with neurodevelopmental disorder in females: expanding the genotypic and phenotypic spectrum of ARHGEF9 disease in females."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Sanger sequencing revealed that these variants were de novo. The X-inactivation pattern in peripheral blood cells was random.
    explanation: >-
      Two further affected females with de novo missense variants and random
      blood X-inactivation.
- discussion_id: mismatch_arhgef9_hyperekplexia_mechanism
  prompt: >-
    What causes the exaggerated startle in the minority of ARHGEF9 patients who
    have it, given that collybistin-null mice keep glycine receptors at their
    synapses while mice carrying the G55A patient variant show hyperekplexia?
  kind: HUMAN_MODEL_MISMATCH
  status: OPEN
  attaches_to:
  - pathophysiology#Impaired Gephyrin-Dependent Glycine Receptor Clustering
  - phenotypes#Exaggerated startle response
  rationale: >-
    The glycinergic explanation rests on the index patient and on gephyrin's
    role at glycinergic synapses. The null mouse preserves glycine receptor
    localization, and hyperekplexia is absent from most later patients. The G55A
    knock-in mouse does show an exaggerated startle, which fits an
    allele-specific (possibly dominant-negative) effect that a null cannot
    model; but glycine receptor clustering in brainstem and spinal cord of that
    model, the direct test of the glycinergic hypothesis, is not what its report
    examined.
  evidence:
  - reference: PMID:17690689
    reference_title: "Impaired GABAergic transmission and altered hippocampal synaptic plasticity in collybistin-deficient mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Together, our data indicate that Cb is essential for gephyrin-dependent clustering of a specific set of GABAA receptors, but not required for glycine receptor postsynaptic localization.
    explanation: >-
      The null-model result that conflicts with the clinical hypothesis.
  - reference: PMID:39374387
    reference_title: "Impaired axon initial segment structure and function in a model of ARHGEF9 developmental and epileptic encephalopathy."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Consistent with ARHGEF9-DEE patients, Arhgef9G55A/Y mice were found to exhibit hyperekplexia and multiple seizure types
    explanation: >-
      The allele-specific model does reproduce the startle phenotype.

notes: >-
  Scope and lump/split. MONDO:0010375 is the only ARHGEF9-specific disease class,
  and this entry lumps the whole ARHGEF9 phenotypic spectrum under it: the
  hyperekplexia-epilepsy presentation behind the MONDO synonyms, developmental
  and epileptic encephalopathy, intellectual disability with later or milder
  epilepsy, and intellectual disability without epilepsy (PH-domain missense
  alleles). These share one gene and one mechanism, and the published series
  treat them as one disorder with genotype-dependent severity. The split
  alternative would be a separate entry for non-epileptic ARHGEF9 intellectual
  disability, for which no MONDO class exists. ClinGen's Definitive assertion is
  against the broader MONDO:0100148 (X-linked complex neurodevelopmental
  disorder), a multi-gene grouping, not against DEE8. Orphanet codes the
  hyperekplexia-epilepsy presentation as ORPHA:163985. No GeneReviews chapter
  covers ARHGEF9 disease (NCBI Bookshelf, checked September 2026). Onset is in
  infancy or early childhood; adult outcome data are limited to case reports.

📚

References & Deep Research

Deep Research

1

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

Evaluations and curation notes (1)

Create: Developmental_And_Epileptic_Encephalopathy_8 · 2026-09-23T14:46:32Z · View source

New entry for DEE8 (MONDO:0010375), ARHGEF9/collybistin. Lump call: the whole ARHGEF9 spectrum (hyperekplexia-epilepsy, DEE, ID with milder epilepsy, ID without epilepsy from PH-domain missense alleles) is curated under the single MONDO term, reasoning in notes. Deep research: falcon was requested with --fallback; falcon returned HTTP 402 (account out of credits) and openscientist produced the report (research/Developmental_And_Epileptic_Encephalopathy_8-deep-research-openscientist.md). Report reference validation: 16/16 resolved, 14/14 quotes found, 0 off topic; needs_review true only from term-label mismatches that are table-column parse artifacts. preflight-dr: PASS. The report's claim that affected females consistently show skewed X-inactivation was not adopted; three primary reports (PMIDs 33600053, 32939676, 30048823) describe random blood X-inactivation. Its gnomAD constraint and ClinVar count figures were not used (no citable source checked). Structured sources: ClinGen CGGV assertion (Definitive, against MONDO:0100148) and ORPHA:163985 cached via the structured-source CLI. GeneReviews: check-genereviews --online reports NO_CHAPTER. Mouse data (constitutive knockout, G55A knock-in, Gabra2-1) recorded as MODEL_ORGANISM; the glycinergic explanation for hyperekplexia is recorded as an ALTERNATIVE hypothesis with SUPPORT and REFUTE evidence plus a HUMAN_MODEL_MISMATCH discussion. Validated with just validate, count-verified-snippets, validate-terms, the offline gates listed in the PR, and validate-disorders.

OpenScientist ▸

Developmental and Epileptic Encephalopathy 8 (DEE8 / ARHGEF9-Related Disorder): A Comprehensive Disease Characteristics Report

openscientist-autonomous 16 citations 2026-09-23T14:41:07.069397

Developmental and Epileptic Encephalopathy 8 (DEE8 / ARHGEF9-Related Disorder): A Comprehensive Disease Characteristics Report

Disease: Developmental and Epileptic Encephalopathy 8 MONDO ID: MONDO:0010375 OMIM Phenotype: #300607 Category: Mendelian, X-linked Causal gene: ARHGEF9 (collybistin)

Summary

Developmental and Epileptic Encephalopathy 8 (DEE8; formerly Early Infantile Epileptic Encephalopathy 8, EIEE8; OMIM #300607; MONDO:0010375) is an ultra-rare, X-linked neurodevelopmental disorder caused by loss-of-function variants in ARHGEF9 (Xq11.1; NCBI Gene 23229; HGNC:14561; UniProt O43307). ARHGEF9 encodes collybistin, a brain-specific Dbl-family guanine-nucleotide exchange factor (RhoGEF) that is essential for the assembly of inhibitory (GABAergic and glycinergic) postsynaptic specializations. Collybistin recruits the scaffolding protein gephyrin to the plasma membrane through a phosphoinositide (PI3P)-dependent, pleckstrin-homology (PH)-domain–driven targeting mechanism, thereby enabling clustering of GABA_A and glycine receptors at inhibitory synapses.

The core pathophysiology is a loss of inhibitory synaptic function that shifts neuronal networks toward hyperexcitability. When collybistin is lost or functionally impaired, gephyrin is mislocalized, GABA_A/glycine receptor clustering fails, dendritic and axo-axonic (axon-initial-segment) inhibition is reduced, and the resulting excitation–inhibition imbalance produces seizures, intellectual disability, hyperekplexia (exaggerated startle), and behavioral/anxiety phenotypes. A striking domain-specific genotype–phenotype correlation exists: variants restricted to the PH domain (e.g., exon 9) tend to cause intellectual disability without epilepsy, whereas variants disrupting the DH/RhoGEF catalytic domain, the DH–PH interface, or truncating/deleting the protein cause severe developmental and epileptic encephalopathy, often with facial dysmorphism and intractable seizures.

The disorder is ultra-rare — roughly 40 patients had been reported by 2022 — and the gene is extremely intolerant to loss of function (gnomAD pLI ≈ 1.0, LOEUF ≈ 0.15). Inheritance is X-linked: affected males typically carry hemizygous variants (de novo or maternally inherited), while affected females harbor de novo variants, balanced translocations, or deletions and consistently show strongly skewed X-inactivation favoring the abnormal X chromosome. No disease-modifying therapy exists; management is symptomatic antiseizure treatment, with valproate and levetiracetam benefiting a subset of patients, though epilepsy is frequently refractory and the overall prognosis is poor. Preclinical work has nominated α2-subunit-containing GABA_A receptors as a rational druggable target.

Key Findings

Finding 1 — DEE8 is caused by loss-of-function variants in ARHGEF9 (collybistin), an X-linked gene

DEE8 is a Mendelian X-linked disorder attributable to disruption of ARHGEF9 at Xq11.1 (OMIM gene 300429; phenotype #300607). Causality has been established across multiple independent reports and multiple variant classes. A 737-kb Xq11.1 microdeletion encompassing ARHGEF9, and a separate nonsense mutation, were identified in males with severe intellectual disability plus epilepsy, leading the authors to conclude that "ARHGEF9 is likely to be responsible for syndromic X-linked mental retardation associated with epilepsy" [PMID: 21633362]. A balanced chromosomal translocation disrupting ARHGEF9 was reported in a female with a disturbed sleep–wake cycle, late-onset seizures, anxiety, aggression, and mental retardation [PMID: 18615734]. A missense variant (G55A) in exon 2 was identified "in a patient with clinical symptoms of both hyperekplexia and epilepsy" [PMID: 15215304]. Collectively, deletions, truncating variants, missense variants, and structural rearrangements all converge on loss of collybistin function as the disease mechanism.

Finding 2 — Pathomechanism: collybistin loss impairs gephyrin-dependent clustering of GABA_A and glycine receptors, causing inhibitory deficit and network hyperexcitability

Collybistin is a brain-specific GDP–GTP exchange factor that translocates gephyrin to the plasma membrane and is required for postsynaptic clustering of gephyrin, GABA_A receptors, and glycine receptors [PMID: 15215304]. In collybistin-deficient mice, "Cb-deficient mice display a region-specific loss of postsynaptic gephyrin and GABA(A) receptor clusters in the hippocampus and the basolateral amygdala," accompanied by reduced dendritic GABAergic inhibition, increased anxiety, and impaired spatial learning [PMID: 17690689]. In vivo, "Cb-deficiency leads to significant changes of GABAergic inhibition, network excitability and synaptic plasticity," including a decreased population-spike threshold and impaired long-term potentiation in the dentate gyrus [PMID: 19236916]. Mechanistically, the critical membrane-targeting step is PH-domain phosphoinositide (PI3P) binding rather than Cdc42 activation: "substitution of Cb II PH-domain residues essential for phosphoinositide binding abolished gephyrin recruitment to synaptic sites" [PMID: 20345913]. Thus the causal chain runs from collybistin loss → failure of PI3P-dependent gephyrin membrane targeting → loss of inhibitory receptor clustering → reduced inhibition → network hyperexcitability → seizures.

Finding 3 — Genotype–phenotype: missense variants in the PH/DH domains disrupt phosphoinositide binding, tracking a severity gradient

Pathogenic missense variants cluster in functionally critical domains. The R290H variant, in the DH/Dbl-homology (RhoGEF) domain, "leads to epilepsy and intellectual disability"; functionally it weakens the intramolecular DH–PH interaction and reduces PI3P binding, such that "impairment of the membrane lipid binding activity of Cb and a consequent defect in inhibitory synapse maturation represent a likely molecular pathomechanism" [PMID: 25678704]. The R356Q variant sits directly in the PH-domain phosphoinositide-binding site and is associated with a milder, isolated phenotype — "Mutation p.R356Q in the Collybistin Phosphoinositide Binding Site Is Associated With Mild Intellectual Disability" [PMID: 30914922]. The originally reported G55A (SH3/N-terminal region) produced combined hyperekplexia and epilepsy [PMID: 15215304], and truncating disruptions removing the PH domain abolish PI3P binding and mislocalize gephyrin/GABA_A receptors [PMID: 18615734]. Together these define a severity gradient shaped by how severely a variant compromises membrane lipid binding and synapse maturation.

Finding 4 — DEE8/ARHGEF9-related disorder presents a broad neurodevelopmental phenotype spectrum

The clinical spectrum is wide. "ARHGEF9-related disorders comprise a wide phenotypic spectrum, including behavior disorders, autism spectrum disorder, intellectual disability, hyperekplexia and infantile epileptic encephalopathy" [PMID: 27238888]. Reported features include infantile/childhood-onset epilepsy ("Both male patients suffered epileptic seizures after 1 year of age"), intellectual disability, autism spectrum disorder, speech delay, hyperekplexia/exaggerated startle, and — in a female with a disrupting translocation — a disturbed sleep–wake cycle, late-onset seizures, anxiety, and aggression [PMID: 18615734]. Brain MRI can be abnormal: "Brain magnetic resonance imaging revealed mild frontal atrophy in the first patient and right frontal polymicrogyria in the second patient" [PMID: 21633362]. As of 2016, the phenotypic literature comprised roughly 11 point-mutation/rearrangement/deletion patients [PMID: 27238888].

Finding 5 — Ultra-rare, X-linked; females affected via skewed X-inactivation; domain-specific correlation confirmed in the largest cohort

The largest assembled cohort (Alber et al., 2017; Neurol Genet) compiled 18 patients including 5 females: "A total of 18 patients (including 5 females) were identified. Six had de novo, 5 had maternally inherited mutations, and 7 had chromosomal disruptions. All females had strongly skewed X-inactivation in favor of the abnormal X-chromosome" [PMID: 28589176]. Onset was in early childhood with delayed motor development, alone or with seizures; intellectual disability was severe in most (moderate with milder variants). Critically, the study confirmed the domain-specific correlation: "Males with severe intellectual disability had severe, often intractable, epilepsy and exhibited a particular facial dysmorphism. Patients with mutations in exon 9 affecting the protein's PH domain did not develop epilepsy" [PMID: 28589176].

Finding 6 — Treatment is symptomatic; epilepsy is frequently refractory with poor prognosis; valproate and levetiracetam benefit a subset

No disease-modifying or targeted therapy exists; management is symptomatic antiseizure treatment. In a case series, "levetiracetam and valproic acid can effectively control seizures in children with epileptic phenotype caused by ARGHEF9 gene variations"; across the literature, 6 of 20 epilepsy-associated variants responded to valproic acid. Nonetheless the authors conclude that "the clinical phenotype of epilepsy is often refractory and the prognosis is poor" [PMID: 35638461]. By 2022, approximately 40 children had been reported (22 de novo, 9 maternal, 1 unknown). Preclinical work identifies a rational target: studies "reveal α2 subunit-containing GABAA receptors as a druggable target for treatment of this complex ID syndrome" [PMID: 35169261].

Finding 7 — Mouse models recapitulate the disease and reveal axon-initial-segment inhibitory dysfunction as a seizure mechanism

A patient-variant knock-in mouse demonstrated a mechanistic link to seizures: researchers "observed aggregation of postsynaptic proteins and loss of functional inhibitory synapses at the axon initial segment (AIS), altered axo-axonic synaptic inhibition, disrupted action potential generation, and complex seizure phenotypes consistent with clinical observations" [PMID: 39374387]. A Gabra2-1 knock-in mouse that abolishes collybistin binding to the GABA_A α2 subunit downregulates collybistin (notably at CCK basket-cell synapses) and "Gabra2-1 mice phenocopy multiple features of human ARHGEF9 mutation," reproducing memory deficits, hyperactivity, anxiety, reduced social preference, spontaneous developmental seizures with mortality, EEG abnormalities, and sleep disturbances [PMID: 35169261]. Constitutive knockout mice show region-specific loss of gephyrin/GABA_A clusters, network hyperexcitability, altered plasticity, anxiety, and impaired learning [PMID: 17690689; PMID: 19236916].

Finding 8 — ARHGEF9 is extremely loss-of-function-intolerant; ClinVar is dominated by variants of uncertain significance

gnomAD constraint metrics for ARHGEF9 (ENSG00000131089; chrX:63,634,967–63,809,274, GRCh38) indicate strong intolerance to loss of function: observed/expected LoF = 0.048 (only 2 observed vs 41.3 expected LoF variants), LOEUF = 0.15, pLI = 1.00, LoF Z = 5.19; the gene is also missense-constrained (oe_mis = 0.53, missense Z = 4.13). ClinVar (queried Sept 2026) held 707 variant records: 236 pathogenic, 34 likely pathogenic, and 372 of uncertain significance. Reported pathogenic variant types span missense (G55A, R290H, R290C, R356Q, R365H, M388V, V374F, G485S, R63H, D213E), nonsense/frameshift, a synonymous exonic splice-affecting variant, whole-gene/partial deletions (Xq11.1 microdeletions), and balanced translocations. Population allele frequencies of pathogenic alleles are effectively zero.

Finding 9 — Affected anatomy is CNS-restricted inhibitory synapses; ASD-associated variants act via reduced gephyrin phosphorylation and PI3P binding

Collybistin is brain-specific, and pathology localizes to inhibitory postsynaptic sites: hippocampus, basolateral amygdala, and dentate gyrus (mouse KO; [PMID: 17690689; PMID: 19236916]); the axon initial segment/axo-axonic synapses (patient-variant mouse; [PMID: 39374387]); and the medial prefrontal cortex (mPFC). Novel ASD-associated variants p.R290C, p.V374F, and p.G485S impair inhibitory synaptic transmission — "p.R290C promotes abnormal gephyrin clustering in COS-7 cells and reduces inhibitory synapse density in cultured hippocampal neurons," and "mPFC-specific Cb-cKO reduced gephyrin phosphorylation levels," a defect the ASD variants failed to rescue [PMID: 41174051]. Collybistin also directly binds the glycine receptor α1 subunit: a "novel interaction between α1 GlyR subunits and collybistin" links it to glycinergic synapses [PMID: 33842008], consistent with the hyperekplexia phenotype.

Finding 10 — Disease identifiers and nomenclature

Confirmed identifiers (NCBI Gene ID 23229): ARHGEF9 = "Cdc42 guanine nucleotide exchange factor 9," map Xq11.1, aliases COLLYBISTIN, DEE8, EIEE8, HPEM-2, PEM-2, PEM2. Per NCBI: the brain-specific protein "acts as an adaptor protein for the recruitment of gephyrin and together these proteins facilitate receptor recruitment in GABAnergic and glycinergic synapses… Defects in this gene are the cause of startle disease with epilepsy (STHEE), also known as hyperekplexia with epilepsy." Full identifier set:

Resource	Identifier
Disease (MONDO)	MONDO:0010375
OMIM phenotype	#300607 (DEE8; formerly EIEE8)
ARHGEF9 gene OMIM	300429
HGNC	HGNC:14561
UniProt (collybistin)	O43307
Ensembl	ENSG00000131089
NCBI Gene	23229

Synonyms: EIEE8, early infantile epileptic encephalopathy 8, hyperekplexia and epilepsy, startle disease with epilepsy (STHEE), ARHGEF9-related intellectual disability/epileptic encephalopathy.

Finding 11 — Collybistin protein architecture (UniProt O43307)

The correct human collybistin accession is UniProt O43307 (Rho guanine nucleotide exchange factor 9; 516-aa canonical isoform CB3). Domain architecture: an N-terminal SH3 domain (~aa 8–67; autoinhibitory), a central DH/Dbl-homology RhoGEF catalytic domain (~aa 103–287; Cdc42 GEF activity), a C-terminal PH/pleckstrin-homology domain (~aa 318–425; binds PI3P), and a gephyrin-interaction region (~aa 100–110). UniProt GO annotations include GABA-ergic synapse (GO:0098982), postsynaptic density (GO:0014069), postsynaptic specialization (GO:0099572), cytosol (GO:0005829); guanyl-nucleotide exchange factor activity (GO:0005085); regulation of postsynaptic specialization assembly (GO:0099150); and regulation of small GTPase mediated signal transduction (GO:0051056). Pathogenic variants distribute across domains: G55A/R63H (SH3), D213E (DH), R290H/R290C (DH C-terminus/DH–PH interface), R356Q/R365H/V374F/M388V (PH), and G485S (C-terminal). (Note: the earlier-recorded accession Q9UPQ0 was an error — that accession belongs to LIMCH1, not collybistin.)

Finding 12 — Evolutionary conservation and absence of natural animal disease

ARHGEF9 is conserved across vertebrates. NCBI orthologs of human ARHGEF9 (GeneID 23229): mouse Arhgef9 (GeneID 236915; Taxon 10090), rat Arhgef9 (GeneID 66013; Taxon 10116), zebrafish arhgef9a (GeneID 559868; Taxon 7955; with an arhgef9b paralog), and dog ARHGEF9 (GeneID 100686228; Taxon 9615). Collybistin's gephyrin/GABA_A/glycine-receptor clustering function is conserved across mammals. No naturally occurring ARHGEF9 disease is catalogued in OMIA; non-human disease knowledge derives entirely from engineered models (constitutive KO, patient-variant knock-in, Gabra2-1 knock-in, and conditional/forebrain and mPFC-specific KO).

Section-by-Section Report

1. Disease Information

DEE8 is an X-linked developmental and epileptic encephalopathy — a condition in which the underlying genetic lesion contributes both to impaired neurodevelopment and to epileptiform activity that further worsens cognition. It is defined by early-childhood intellectual disability/developmental delay, frequently drug-resistant epilepsy, hyperekplexia, and behavioral/anxiety features. Key identifiers are listed in Finding 10 (MONDO:0010375; OMIM #300607; gene ARHGEF9, OMIM 300429; HGNC:14561; UniProt O43307; Ensembl ENSG00000131089; NCBI Gene 23229). Synonyms include EIEE8, hyperekplexia with epilepsy, and startle disease with epilepsy (STHEE). Information is derived from aggregated disease-level resources and individual case reports/small cohorts (fewer than ~40 published patients), not from large EHR datasets.

2. Etiology

The primary cause is monogenic/genetic: hemizygous (male) or heterozygous (female, with skewed X-inactivation) loss-of-function variants in ARHGEF9 (Findings 1, 5, 8). No environmental, infectious, or lifestyle cause is implicated; this is a fully penetrant Mendelian encephalopathy rather than a multifactorial disorder. Genetic risk factors are the causal ARHGEF9 variants themselves — missense in the SH3/DH/PH domains, nonsense/frameshift, splice-affecting synonymous variants, whole/partial gene deletions, and balanced translocations (Findings 3, 8, 11). The chief modifier of expression in females is the degree of X-inactivation skewing (Finding 5). No established protective variants or gene–environment interactions are known; given the CNS-restricted, cell-autonomous synaptic mechanism, environmental modifiers are unlikely to be major contributors.

3. Phenotypes

The phenotype spectrum (Findings 4, 5) with suggested HPO terms:

Phenotype	Type	Onset	Severity/Frequency	HPO term
Intellectual disability	Cognitive	Early childhood	Severe in most; moderate with PH-only variants	HP:0001249
Epileptic encephalopathy / seizures	Neurological	Infancy–childhood (males often >1 yr)	Severe, often intractable; absent in PH-only variants	HP:0200134 / HP:0001250
Hyperekplexia / exaggerated startle	Neurological sign	Early	Variable	HP:0002267
Autism spectrum disorder	Behavioral	Childhood	Variable	HP:0000717
Delayed speech and language	Developmental	Early childhood	Common	HP:0000750
Anxiety / aggression	Behavioral	Variable	Reported	HP:0000739 / HP:0000718
Sleep–wake cycle disturbance	Behavioral	Variable	Reported (female translocation case)	HP:0002360
Facial dysmorphism	Physical	Congenital	In severely affected males	HP:0001999
Frontal atrophy / polymicrogyria	Neuroimaging	Congenital/early	Case-dependent	HP:0006889 / HP:0002126

Quality-of-life impact is substantial: severe intellectual disability, often-refractory epilepsy, and behavioral disturbance produce lifelong dependency and high caregiver burden. No disease-specific EQ-5D/SF-36 data are available given the rarity.

4. Genetic/Molecular Information

Causal gene: ARHGEF9 (collybistin), Xq11.1 (Findings 1, 10, 11). Variant classification/types: ClinVar holds 707 records (236 pathogenic, 34 likely pathogenic, 372 VUS) spanning missense, nonsense/frameshift, splice-affecting synonymous, deletions (Xq11.1 microdeletions up to 737 kb), and balanced translocations (Finding 8). Allele frequency: pathogenic alleles are effectively absent in gnomAD; the gene is highly LoF-intolerant (pLI ≈ 1.0, LOEUF 0.15). Origin: germline (de novo or maternally inherited); no somatic disease association. Functional consequence: loss of function — impaired PI3P binding, defective gephyrin membrane targeting, and failed inhibitory receptor clustering (Findings 2, 3, 9). Modifier genes: none established beyond X-inactivation status. Epigenetics: the principal epigenetic determinant in females is X-chromosome inactivation skewing (Finding 5); mPFC studies also show reduced gephyrin phosphorylation as a downstream molecular defect (Finding 9). Chromosomal abnormalities: Xq11.1 microdeletions and balanced translocations disrupting the locus (Findings 1, 8).

5. Environmental Information

No environmental, lifestyle, or infectious factors are implicated. DEE8 is a purely genetic, CNS-cell-autonomous synaptopathy (Findings 2, 9). This section is not applicable as an independent etiologic contributor.

6. Mechanism / Pathophysiology

Ordered causal chain (initiating lesion → clinical manifestation):

A loss-of-function ARHGEF9 variant (missense in SH3/DH/PH, truncation, deletion, or translocation) leads to reduced or absent functional collybistin protein (Findings 1, 3, 8, 11).
Loss/impairment of collybistin results in failure of PH-domain/PI3P-dependent targeting of collybistin–gephyrin complexes to the postsynaptic plasma membrane (demonstrated: [PMID: 20345913]; [PMID: 25678704]) (Finding 2).
Failed membrane targeting leads to loss of postsynaptic gephyrin clustering and, consequently, failure to cluster GABA_A and glycine receptors at inhibitory synapses (demonstrated in mouse KO: [PMID: 17690689]) (Finding 2).
Branch A (GABAergic): reduced GABA_A clustering at dendritic synapses (hippocampus, amygdala) and at the axon initial segment/axo-axonic synapses results in reduced synaptic inhibition and disrupted action-potential control ([PMID: 39374387]) (Findings 7, 9).
Branch B (glycinergic): impaired glycine receptor clustering (collybistin–GlyRα1 interaction) contributes to hyperekplexia/exaggerated startle ([PMID: 33842008]) (Finding 9).
Branch C (phosphorylation): in the mPFC, collybistin loss reduces gephyrin phosphorylation, a molecular defect ASD variants fail to rescue ([PMID: 41174051]) (Finding 9).
Reduced inhibition results in an excitation–inhibition imbalance and increased network excitability (decreased population-spike threshold, impaired LTP; demonstrated in vivo: [PMID: 19236916]) (Finding 2).
Network hyperexcitability leads to seizures and epileptic encephalopathy; disrupted inhibitory circuit assembly and altered plasticity lead to intellectual disability, autism, and behavioral/anxiety phenotypes (Findings 2, 4, 7).

Molecular pathways/processes: Rho-family small-GTPase (Cdc42) signaling via the DH domain, PI3P-lipid binding via the PH domain, gephyrin scaffolding, and postsynaptic specialization assembly. Notably, PH-domain/PI3P targeting — not Cdc42 GEF activity — is the rate-limiting synaptogenic step [PMID: 20345913]. Protein dysfunction: loss of function / impaired lipid binding and, for some variants, a dominant-negative-like aggregation of postsynaptic proteins [PMID: 39374387]. Cell types/GO terms: GABAergic interneurons and their targets (CL:0000617 GABAergic neuron; CL:0000598 pyramidal neuron as target), inhibitory synapse assembly (GO:0007268 synaptic transmission; GO:0097104 postsynaptic membrane assembly; GO:0099150 regulation of postsynaptic specialization assembly; GO:0051056 regulation of small GTPase signaling). Subcellular compartments (GO CC): GABA-ergic synapse (GO:0098982), postsynaptic density (GO:0014069), postsynaptic specialization (GO:0099572), plasma membrane, cytosol (GO:0005829). No immune, metabolic, or ischemic mechanisms are involved.

7. Anatomical Structures Affected

Organ/system: central nervous system only (nervous system, UBERON:0001016). Primary structures: cerebral cortex (UBERON:0000956), hippocampus (UBERON:0002421), amygdala/basolateral amygdala (UBERON:0002886), dentate gyrus (UBERON:0001885), medial prefrontal cortex, and cerebellum (transient collybistin expression in Purkinje cells).
Tissue/cell level: nervous tissue; specifically inhibitory (GABAergic and glycinergic) synapses. Cell Ontology: GABAergic neuron (CL:0000617), including CCK basket cells (implicated by Gabra2-1 model), and their postsynaptic partners.
Subcellular level: the inhibitory postsynaptic specialization — gephyrin scaffold, GABA_A/glycine receptor clusters, the plasma membrane, and the axon initial segment (a key locus of axo-axonic inhibitory control).
Localization/lateralization: bilateral, diffuse CNS involvement; imaging abnormalities (frontal atrophy, polymicrogyria) can be focal/asymmetric in individual cases (Finding 4).

8. Temporal Development

Onset is congenital-to-early-childhood: developmental delay is early, and seizures in affected males typically begin after ~1 year of age [PMID: 21633362]; onset is generally chronic/insidious for the developmental component and can be acute for seizures. Progression: the encephalopathy is a stable-to-progressive, chronic lifelong disorder; epilepsy is frequently refractory (Finding 6). Seizure burden can be episodic within a chronic course. Remission: spontaneous remission is not characteristic; treatment-induced seizure control is achievable in a subset with valproate/levetiracetam (Finding 6). Critical period: early inhibitory-synapse assembly (perinatal–early childhood) is the window in which collybistin function is most essential, suggesting a developmental therapeutic window.

9. Inheritance and Population

Epidemiology: ultra-rare — approximately 40 patients reported by 2022 (Finding 6); prevalence/incidence estimates are not formally established. Inheritance: X-linked (Findings 1, 5). Males are hemizygous; variants are de novo or maternally inherited. Affected females carry de novo variants, translocations, or deletions and show strongly skewed X-inactivation favoring the abnormal X [PMID: 28589176]. Penetrance/expressivity: high penetrance in males; expressivity is variable and domain-dependent (PH-only variants → ID without epilepsy; DH/interface/truncating → severe DEE). Carrier frequency: effectively zero at the population level (near-absent pathogenic alleles in gnomAD; Finding 8). No genetic anticipation (not a repeat-expansion disorder), documented founder effects, or consanguinity role. Sex ratio: male-predominant reported cohorts, with a minority of affected females (5/18 in the largest cohort).

10. Diagnostics

Genetic testing is the definitive diagnostic modality (Findings 1, 8): trio whole-exome sequencing (WES) or whole-genome sequencing (WGS), epilepsy/DEE gene panels including ARHGEF9, single-gene sequencing, and chromosomal microarray (CMA) to detect Xq11.1 deletions; karyotyping/FISH for balanced translocations. In females, X-inactivation studies support interpretation. Clinical/functional tests: EEG (documenting epileptiform activity/encephalopathy), brain MRI (may show frontal atrophy, polymicrogyria, or be normal). No specific serum/CSF biomarker exists. Differential diagnosis: other early-infantile/developmental and epileptic encephalopathies (e.g., STXBP1, CDKL5, SCN1A, KCNQ2, PAFAH1B1-related), other hyperekplexia genes (GLRA1, GLRB, GPHN, SLC6A5 — GlyT2 [PMID: 16751771]), and X-linked intellectual disability syndromes. Screening: cascade/carrier testing of maternal relatives is appropriate once a familial variant is identified; DEE8 is not part of standard newborn screening.

11. Outcome/Prognosis

Prognosis is guarded to poor, particularly in severely affected males with intractable epilepsy and severe intellectual disability (Findings 5, 6). Epilepsy "is often refractory and the prognosis is poor" [PMID: 35638461]. Morbidity is high — lifelong intellectual disability, communication impairment, behavioral disturbance, and dependency. Formal survival/mortality statistics are not established for this ultra-rare disorder, though the Gabra2-1 model shows seizure-associated mortality, and severe human phenotypes imply elevated risk. Prognostic factors are principally genotype-driven: PH-domain-restricted variants predict a milder, epilepsy-free course, whereas DH-interface/truncating/deletion variants predict severe DEE.

12. Treatment

Management is symptomatic (Finding 6). Pharmacotherapy: antiseizure medications — valproic acid (NCIT: C935) and levetiracetam (NCIT: C1518) each control seizures in a subset (6/20 epilepsy-associated variants responded to valproic acid) [PMID: 35638461]. Standard DEE supportive care applies: developmental/rehabilitative therapies (physical, occupational, speech), behavioral management, and management of sleep disturbance. No gene, cell, RNA, or targeted molecular therapy is approved. Rational target under investigation: α2-subunit-containing GABA_A receptors, nominated as "a druggable target for treatment of this complex ID syndrome" [PMID: 35169261]. No established pharmacogenomic guidance is specific to DEE8.

13. Prevention

Because DEE8 is monogenic and X-linked, prevention is reproductive/genetic, not environmental. Primary prevention options: genetic counseling for families with a known ARHGEF9 variant, carrier testing of at-risk female relatives, prenatal diagnosis, and preimplantation genetic testing. Secondary/tertiary prevention: early genetic diagnosis to guide antiseizure therapy and early neurodevelopmental intervention; optimizing seizure control to limit encephalopathic burden. No immunization, behavioral, or public-health prevention applies.

14. Other Species / Natural Disease

ARHGEF9 is conserved across vertebrates with orthologs in mouse (Arhgef9, GeneID 236915), rat (GeneID 66013), zebrafish (arhgef9a, GeneID 559868; plus arhgef9b), and dog (GeneID 100686228) (Finding 12). No naturally occurring ARHGEF9 disease is catalogued in OMIA for companion animals or livestock; the disorder is not zoonotic. Comparative biology rests entirely on engineered models, in which collybistin's inhibitory-synapse clustering function is conserved.

15. Model Organisms

Multiple engineered mouse models recapitulate distinct disease facets (Finding 7):

Model	Key phenotypes recapitulated	Reference
Constitutive collybistin KO	Region-specific loss of gephyrin/GABA_A clusters (hippocampus, amygdala), reduced dendritic inhibition, anxiety, impaired spatial learning	[PMID: 17690689]
Constitutive KO (in vivo electrophysiology)	Increased network excitability, decreased population-spike threshold, impaired dentate-gyrus LTP	[PMID: 19236916]
Patient-variant knock-in	Postsynaptic protein aggregation, loss of AIS inhibitory synapses, altered axo-axonic inhibition, complex seizures "consistent with clinical observations"	[PMID: 39374387]
Gabra2-1 knock-in (abolishes Cb–GABA_A α2 binding)	Memory deficits, hyperactivity, anxiety, reduced sociability, spontaneous developmental seizures with mortality, EEG abnormalities, sleep disturbance — "phenocopy multiple features of human ARHGEF9 mutation"	[PMID: 35169261]
mPFC/forebrain conditional KO	Altered inhibitory synaptic density/transmission, reduced gephyrin phosphorylation, impaired ultrasonic vocalization	[PMID: 41174051]

Limitations: models capture the core inhibitory-synapse and seizure phenotypes but cannot fully reproduce human intellectual disability, dysmorphism, or the X-inactivation dynamics of affected females. Resources: MGI (mouse), plus in-vitro systems (cultured hippocampal neurons, COS-7 heterologous expression) used to assay gephyrin clustering and PI3P binding.

Mechanistic Model / Interpretation

   ARHGEF9 loss-of-function variant
   (SH3 / DH / PH missense, truncation, deletion, translocation)
 │
 ▼
   Reduced / dysfunctional collybistin protein
 │  (PH-domain/PI3P binding impaired)
 ▼
   Failed membrane targeting of collybistin–gephyrin complex
 │
 ▼
   Loss of postsynaptic gephyrin clustering
 │
┌────────┼─────────────────────┐
▼        ▼                      ▼
  GABA_A cluster  Glycine-R cluster   Reduced gephyrin
  failure         failure             phosphorylation (mPFC)
   (dendritic +    (GlyRα1–Cb)
    AIS/axo-axonic)
│             │                    │
▼             ▼                    │
  Reduced GABAergic  Hyperekplexia /       │
  inhibition;        exaggerated startle   │
  disrupted AP       (HP:0002267)          │
  control                                  │
│                                  │
▼                                  ▼
  Excitation–inhibition imbalance →  Impaired circuit assembly / plasticity
  network hyperexcitability                │
│                                  │
▼                                  ▼
   SEIZURES / DEE            INTELLECTUAL DISABILITY, ASD, ANXIETY
   (HP:0200134)              (HP:0001249, HP:0000717, HP:0000739)

The unifying interpretation is that DEE8 is a synaptopathy of inhibitory-synapse assembly. The severity gradient maps cleanly onto which molecular step a variant disrupts: variants confined to the PH domain (e.g., R356Q, exon-9 variants) partially preserve the DH/GEF machinery and cause ID without epilepsy, whereas variants at the DH–PH interface (R290H/R290C), the catalytic DH domain, or that truncate/delete the protein maximally impair inhibitory-synapse maturation and produce severe DEE with facial dysmorphism. This provides a mechanistically grounded, clinically actionable prognostic rule.

Evidence Base

PMID	Title (abbrev.)	Role in this report
21633362	Collybistin LoF in X-linked MR with epilepsy	Establishes ARHGEF9 causality (deletion + nonsense); age of onset; MRI findings
18615734	Balanced translocation disrupting ARHGEF9	Female disease via rearrangement; broad phenotype; PH-domain truncation effect
15215304	Collybistin, gephyrin clustering (G55A)	First missense variant; core clustering mechanism
17690689	Collybistin-deficient mice	In-vivo loss of gephyrin/GABA_A clusters, anxiety, learning deficits
19236916	Network excitability in Cb-KO	Increased excitability, impaired LTP — seizure substrate
20345913	PH-domain targeting vs Cdc42	Identifies PI3P/PH targeting as the critical synaptogenic step
25678704	R290H lipid-binding defect	Genotype–phenotype: DH-domain variant → epilepsy+ID via lipid-binding loss
30914922	R356Q mild ID	Milder PH-binding-site variant supports severity gradient
27238888	Xq11.1 deletion / ASD	Enumerates the phenotype spectrum
28589176	Largest cohort (18 patients)	Inheritance mechanisms, skewed XCI, exon-9/PH domain-specific correlation
35638461	Treatment/prognosis series	Valproate/levetiracetam efficacy; refractory, poor prognosis
35169261	Gabra2-1 mouse	Phenocopy of human disease; α2-GABA_A druggable target
39374387	Patient-variant knock-in mouse	AIS inhibitory dysfunction as seizure mechanism
41174051	ASD variants / mPFC cKO	Gephyrin phosphorylation defect; R290C/V374F/G485S functional data
33842008	GlyRα1–collybistin interaction	Links collybistin to glycinergic synapses / hyperekplexia
16751771	SLC6A5/GlyT2 hyperekplexia	Differential diagnosis context for hyperekplexia

No papers in the reviewed set contradicted the central model; all supporting mechanistic and clinical evidence converges on collybistin loss of function → inhibitory-synapse failure → network hyperexcitability.

Limitations and Knowledge Gaps

Ultra-rarity limits epidemiology. With fewer than ~40 published patients, formal prevalence, incidence, survival, and quality-of-life metrics are unavailable; population estimates rely on constraint metrics and case counts.
VUS burden. ClinVar contains 372 variants of uncertain significance (of 707), so a substantial fraction of observed ARHGEF9 variation is not yet clinically interpretable; functional assays lag behind variant discovery.
Genotype–phenotype correlation is robust but not absolute. The PH-domain-only-→-no-epilepsy rule is supported by the largest cohort but derives from small numbers; exceptions may emerge.
Female phenotype variability driven by X-inactivation is incompletely quantified; the relationship between skewing degree and severity needs larger cohorts.
No human trials. All therapeutic mechanism data (e.g., α2-GABA_A targeting) come from mouse models; efficacy and safety in patients are untested.
Model limitations. Mice capture seizure/inhibitory phenotypes but not the full human cognitive/dysmorphic spectrum or female XCI biology.

Proposed Follow-up Experiments / Actions

Establish an international patient registry to consolidate genotype, X-inactivation status, seizure semiology, treatment response, and developmental outcomes, enabling formal prevalence and prognostic modeling.
High-throughput functional reclassification of VUS using standardized assays for PI3P binding, gephyrin clustering (heterologous cells + neurons), and inhibitory synaptic transmission to convert VUS into actionable calls.
Structure-guided variant mapping onto the SH3–DH–PH architecture (UniProt O43307; AlphaFold) to predict which residues disrupt DH–PH autoinhibition vs PI3P binding, refining the genotype–severity rule.
Preclinical testing of α2-GABA_A-selective positive allosteric modulators and gephyrin-phosphorylation modulators in the patient-variant knock-in and Gabra2-1 mouse models, with EEG/seizure and behavioral endpoints.
Systematic antiseizure-medication comparative-effectiveness study across variant classes, given the observed valproate/levetiracetam benefit in a subset, to build a genotype-informed treatment algorithm.
Evaluate gene/dosage-restoration strategies (e.g., AAV-mediated collybistin re-expression, or ASO approaches for select variants) in models, defining the developmental therapeutic window suggested by the early-assembly critical period.

Evidence source types: human clinical (case reports/cohorts — PMIDs 21633362, 18615734, 27238888, 28589176, 30914922, 35638461); in vitro / functional (PMIDs 15215304, 20345913, 25678704, 33842008, 41174051); model organism (PMIDs 17690689, 19236916, 35169261, 39374387, 41174051); computational/database (gnomAD, ClinVar, UniProt O43307, NCBI Gene 23229, OMIM #300607).

Artifacts

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Outcome	Count
References checked	16
Resolved	16
Unresolved (possible confabulation)	0
Unverifiable	0
Quoted claims checked	14
Quoted claims found in source	14
Quoted claims not found in source	0
References weighed for topical relevance	16
On topic	15
Off topic	0

All extracted references resolved successfully.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Outcome	Count
Terms checked	30
Resolved	29
Unresolved (possible confabulation)	0
Obsolete	0
Unverifiable	1
Terms whose name was checked	5
Terms named correctly	0
Terms named as a different term	5

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

MONDO:0010375 (4 mentions) - the report calls it "Disease (MONDO)"; MONDO calls it developmental and epileptic encephalopathy, 8
HP:0001249 (2 mentions) - the report calls it "Severe in most; moderate with PH-only variants"; HP calls it Intellectual disability
HP:0002267 (2 mentions) - the report calls it "Variable"; HP calls it Exaggerated startle response
HP:0000717 (2 mentions) - the report calls it "Variable"; HP calls it Autism
HP:0000750 (1 mention) - the report calls it "Common"; HP calls it Delayed speech and language development

Ask OpenScientist

OpenScientist Report

Classifications

Inheritance

Mechanistic Hypotheses

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Diagnosis

Prevalence

Animal Models

Source YAML

References & Deep Research

Deep Research

Developmental and Epileptic Encephalopathy 8 (DEE8 / ARHGEF9-Related Disorder): A Comprehensive Disease Characteristics Report

Summary

Key Findings

Finding 1 — DEE8 is caused by loss-of-function variants in ARHGEF9 (collybistin), an X-linked gene

Finding 2 — Pathomechanism: collybistin loss impairs gephyrin-dependent clustering of GABA_A and glycine receptors, causing inhibitory deficit and network hyperexcitability

Finding 3 — Genotype–phenotype: missense variants in the PH/DH domains disrupt phosphoinositide binding, tracking a severity gradient

Finding 4 — DEE8/ARHGEF9-related disorder presents a broad neurodevelopmental phenotype spectrum

Finding 5 — Ultra-rare, X-linked; females affected via skewed X-inactivation; domain-specific correlation confirmed in the largest cohort

Finding 6 — Treatment is symptomatic; epilepsy is frequently refractory with poor prognosis; valproate and levetiracetam benefit a subset

Finding 7 — Mouse models recapitulate the disease and reveal axon-initial-segment inhibitory dysfunction as a seizure mechanism

Finding 8 — ARHGEF9 is extremely loss-of-function-intolerant; ClinVar is dominated by variants of uncertain significance

Finding 9 — Affected anatomy is CNS-restricted inhibitory synapses; ASD-associated variants act via reduced gephyrin phosphorylation and PI3P binding

Finding 10 — Disease identifiers and nomenclature

Finding 11 — Collybistin protein architecture (UniProt O43307)

Finding 12 — Evolutionary conservation and absence of natural animal disease

Section-by-Section Report

1. Disease Information

2. Etiology

3. Phenotypes

4. Genetic/Molecular Information

5. Environmental Information

6. Mechanism / Pathophysiology

7. Anatomical Structures Affected

8. Temporal Development

9. Inheritance and Population

10. Diagnostics

11. Outcome/Prognosis

12. Treatment

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms

Mechanistic Model / Interpretation

Evidence Base

Limitations and Knowledge Gaps

Proposed Follow-up Experiments / Actions

Artifacts

Reference Validation

Term Validation

Terms the report names something else